US20140147687A1 - Biologically absorbable coating for implantable devices based on copolymers having ester bonds and methods of fabricating the same - Google Patents
Biologically absorbable coating for implantable devices based on copolymers having ester bonds and methods of fabricating the same Download PDFInfo
- Publication number
- US20140147687A1 US20140147687A1 US14/168,903 US201414168903A US2014147687A1 US 20140147687 A1 US20140147687 A1 US 20140147687A1 US 201414168903 A US201414168903 A US 201414168903A US 2014147687 A1 US2014147687 A1 US 2014147687A1
- Authority
- US
- United States
- Prior art keywords
- poly
- acid
- group
- copolymer
- reagent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 0 N[Y]N.O=C([2*]O)N[Y]NC(=O)[2*]O.OCO.[1*]C(N)C(=O)OCOC(=O)C([1*])N Chemical compound N[Y]N.O=C([2*]O)N[Y]NC(=O)[2*]O.OCO.[1*]C(N)C(=O)OCOC(=O)C([1*])N 0.000 description 21
- YRKCREAYFQTBPV-UHFFFAOYSA-N CC(=O)CC(C)=O Chemical compound CC(=O)CC(C)=O YRKCREAYFQTBPV-UHFFFAOYSA-N 0.000 description 3
- VLJXXKKOSFGPHI-UHFFFAOYSA-N CCCC(C)CC Chemical compound CCCC(C)CC VLJXXKKOSFGPHI-UHFFFAOYSA-N 0.000 description 2
- SWGTZZMHXFBCEL-UHFFFAOYSA-N C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.CNC(CC(C)C)C(=O)OCOC(=O)C(CC(C)C)NC(=O)CC(=O)NCNC(=O)CC(C)=O.CNC(CC(C)C)C(=O)OCOC(=O)C(CC(C)C)NC(=O)CC(C)=O.CNC(CC(C)C)C(=O)OCOC(=O)C(CC(C)C)NC(=O)CCCCCCCCC(=O)OCCCCCCOC(=O)CCCCCCCCC(C)=O.CNCNC(=O)CC(=O)OCOC(=O)CC(C)=O.COC(C)C(=O)NCNC(=O)C(C)OC(=O)CC(=O)NCNC(=O)CC(C)=O.COC(C)C(=O)NCNC(=O)C(C)OC(=O)CC(=O)OCOC(=O)CC(C)=O.COC(C)C(=O)NCNC(=O)C(C)OC(=O)CC(C)=O.COCOC(=O)CC(=O)NCNC(=O)CC(C)=O Chemical compound C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.CNC(CC(C)C)C(=O)OCOC(=O)C(CC(C)C)NC(=O)CC(=O)NCNC(=O)CC(C)=O.CNC(CC(C)C)C(=O)OCOC(=O)C(CC(C)C)NC(=O)CC(C)=O.CNC(CC(C)C)C(=O)OCOC(=O)C(CC(C)C)NC(=O)CCCCCCCCC(=O)OCCCCCCOC(=O)CCCCCCCCC(C)=O.CNCNC(=O)CC(=O)OCOC(=O)CC(C)=O.COC(C)C(=O)NCNC(=O)C(C)OC(=O)CC(=O)NCNC(=O)CC(C)=O.COC(C)C(=O)NCNC(=O)C(C)OC(=O)CC(=O)OCOC(=O)CC(C)=O.COC(C)C(=O)NCNC(=O)C(C)OC(=O)CC(C)=O.COCOC(=O)CC(=O)NCNC(=O)CC(C)=O SWGTZZMHXFBCEL-UHFFFAOYSA-N 0.000 description 1
- LNYAUFMSJRSWHL-UHFFFAOYSA-N C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.CCNC(=O)C(C)OC.CCNC(=O)C(C)OC.CCOC(=O)C(CC(C)C)NC.CNC(=O)C(C)OC(=O)CC(=O)NC(CC(C)C)C(=O)OCOC(=O)C(CC(C)C)NC(=O)CC(C)=O.CNC(=O)C(C)OC(=O)CC(=O)OC(C)C(=O)NCNC(=O)C(C)OC(=O)CC(C)=O.CNCNC(=O)CC(=O)OC(C)C(=O)NCNC(=O)C(C)OC(=O)CC(C)=O.COC(=O)C(CC(C)C)NC(=O)CC(=O)OC(C)C(=O)NCNC(=O)C(C)OC(=O)CC(C)=O.COCOC(=O)CC(=O)OC(C)C(=O)NCNC(=O)C(C)OC(=O)CC(C)=O Chemical compound C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.CCNC(=O)C(C)OC.CCNC(=O)C(C)OC.CCOC(=O)C(CC(C)C)NC.CNC(=O)C(C)OC(=O)CC(=O)NC(CC(C)C)C(=O)OCOC(=O)C(CC(C)C)NC(=O)CC(C)=O.CNC(=O)C(C)OC(=O)CC(=O)OC(C)C(=O)NCNC(=O)C(C)OC(=O)CC(C)=O.CNCNC(=O)CC(=O)OC(C)C(=O)NCNC(=O)C(C)OC(=O)CC(C)=O.COC(=O)C(CC(C)C)NC(=O)CC(=O)OC(C)C(=O)NCNC(=O)C(C)OC(=O)CC(C)=O.COCOC(=O)CC(=O)OC(C)C(=O)NCNC(=O)C(C)OC(=O)CC(C)=O LNYAUFMSJRSWHL-UHFFFAOYSA-N 0.000 description 1
- UGGGHQRTPFBBAC-UHFFFAOYSA-N C.C.C.C.C.C.C.C.C.C.C.C.C.C.CCOC(=O)C(C)NC(=O)CC(=O)NC(C)C(=O)OCOC(=O)C(C)NC(=O)CC(C)=O.CCOC(=O)C(CC(C)C)NC.CCOC(=O)C(CC(C)C)NC(=O)CCCCCCCCC(=O)NC(CC(C)C)C(=O)OCCCCCCOC(=O)C(CC(C)C)NC(=O)CCCCCCCCC(C)=O.CNC(C)C(=O)OC.CNC(CC(C)C)C(=O)OC.CNCNC(=O)CC(=O)NC(CC(C)C)C(=O)OCOC(=O)C(CC(C)C)NC(=O)CC(C)=O.COC(=O)C(CC(C)C)NC(=O)c1ccc(C(=O)NC(CC(C)C)C(=O)OCOC(=O)C(CC(C)C)NC(=O)c2ccc(C(C)=O)cc2)cc1 Chemical compound C.C.C.C.C.C.C.C.C.C.C.C.C.C.CCOC(=O)C(C)NC(=O)CC(=O)NC(C)C(=O)OCOC(=O)C(C)NC(=O)CC(C)=O.CCOC(=O)C(CC(C)C)NC.CCOC(=O)C(CC(C)C)NC(=O)CCCCCCCCC(=O)NC(CC(C)C)C(=O)OCCCCCCOC(=O)C(CC(C)C)NC(=O)CCCCCCCCC(C)=O.CNC(C)C(=O)OC.CNC(CC(C)C)C(=O)OC.CNCNC(=O)CC(=O)NC(CC(C)C)C(=O)OCOC(=O)C(CC(C)C)NC(=O)CC(C)=O.COC(=O)C(CC(C)C)NC(=O)c1ccc(C(=O)NC(CC(C)C)C(=O)OCOC(=O)C(CC(C)C)NC(=O)c2ccc(C(C)=O)cc2)cc1 UGGGHQRTPFBBAC-UHFFFAOYSA-N 0.000 description 1
- HYIFMRCTHBQOMY-UHFFFAOYSA-N C.C.C.C.C.C.C.C.C.CCC(=O)C(C)OC(=O)C1=CC=C(C(=O)OC(C)C(=O)NCNC(=O)C(C)OC(=O)C2=CC=C(C(C)=O)C=C2)C=C1.CCC(=O)CC(=O)NCCCCNC(=O)CC(C)=O.CCOC(=O)C(C)NC.CNC(CC(C)C)C(C)=O.COC(=O)C(C)NC(=O)CC(=O)NC(C)C(=O)OCOC(=O)C(C)NC(=O)CC(C)=O.COC(C)C(C)=O.COCOC(=O)C(CC(C)C)NC(=O)CC(=O)NC(CC(C)C)C(=O)OCOC(=O)C(CC(C)C)NC(=O)CC(C)=O Chemical compound C.C.C.C.C.C.C.C.C.CCC(=O)C(C)OC(=O)C1=CC=C(C(=O)OC(C)C(=O)NCNC(=O)C(C)OC(=O)C2=CC=C(C(C)=O)C=C2)C=C1.CCC(=O)CC(=O)NCCCCNC(=O)CC(C)=O.CCOC(=O)C(C)NC.CNC(CC(C)C)C(C)=O.COC(=O)C(C)NC(=O)CC(=O)NC(C)C(=O)OCOC(=O)C(C)NC(=O)CC(C)=O.COC(C)C(C)=O.COCOC(=O)C(CC(C)C)NC(=O)CC(=O)NC(CC(C)C)C(=O)OCOC(=O)C(CC(C)C)NC(=O)CC(C)=O HYIFMRCTHBQOMY-UHFFFAOYSA-N 0.000 description 1
- PNWWXHVNRIYZJG-UHFFFAOYSA-N C.C.C.C.C.C.CNCC(CC(C)C)O(=O)COC(=O)C(CC(C)C)NC(=O)CC(=O)OC(C)C(=O)NCNC(=O)C(C)OC(=O)CC(C)=O Chemical compound C.C.C.C.C.C.CNCC(CC(C)C)O(=O)COC(=O)C(CC(C)C)NC(=O)CC(=O)OC(C)C(=O)NCNC(=O)C(C)OC(=O)CC(C)=O PNWWXHVNRIYZJG-UHFFFAOYSA-N 0.000 description 1
- DHAFTRGZPMNVJN-UHFFFAOYSA-N C.C.C.C.C.C.CNCNC(=O)CC(=O)OC(C)C(=O)NCNC(=O)C(C)OC(=O)CC(C)=O Chemical compound C.C.C.C.C.C.CNCNC(=O)CC(=O)OC(C)C(=O)NCNC(=O)C(C)OC(=O)CC(C)=O DHAFTRGZPMNVJN-UHFFFAOYSA-N 0.000 description 1
- LDERSDFVBUDSNA-UHFFFAOYSA-N C.C.C.C.C.C.COC(C)C(=O)NCNC(=O)C(C)OC(=O)CC(=O)NC(CC(C)C)C(=O)OCOC(=O)C(CC(C)C)NC(=O)CC(C)=O Chemical compound C.C.C.C.C.C.COC(C)C(=O)NCNC(=O)C(C)OC(=O)CC(=O)NC(CC(C)C)C(=O)OCOC(=O)C(CC(C)C)NC(=O)CC(C)=O LDERSDFVBUDSNA-UHFFFAOYSA-N 0.000 description 1
- ZFHHVCCLKQRKFJ-UHFFFAOYSA-N C.C.C.C.C.C.COC(C)C(=O)NCNC(=O)C(C)OC(=O)CC(=O)NCNC(=O)CC(C)=O Chemical compound C.C.C.C.C.C.COC(C)C(=O)NCNC(=O)C(C)OC(=O)CC(=O)NCNC(=O)CC(C)=O ZFHHVCCLKQRKFJ-UHFFFAOYSA-N 0.000 description 1
- OUCYASZAGKDYGN-UHFFFAOYSA-N C.C.C.C.C.C.COC(C)C(=O)NCNC(=O)C(C)OC(=O)CC(=O)OC(C)C(=O)NCNC(=O)C(C)OC(=O)CC(C)=O Chemical compound C.C.C.C.C.C.COC(C)C(=O)NCNC(=O)C(C)OC(=O)CC(=O)OC(C)C(=O)NCNC(=O)C(C)OC(=O)CC(C)=O OUCYASZAGKDYGN-UHFFFAOYSA-N 0.000 description 1
- NBDNSIMEYJNWHA-UHFFFAOYSA-N C.C.C.C.C.C.COC(C)C(=O)NCNC(=O)C(C)OC(=O)CC(=O)OCOC(=O)CC(C)=O Chemical compound C.C.C.C.C.C.COC(C)C(=O)NCNC(=O)C(C)OC(=O)CC(=O)OCOC(=O)CC(C)=O NBDNSIMEYJNWHA-UHFFFAOYSA-N 0.000 description 1
- HPOXOSWBYZBHHP-UHFFFAOYSA-N C.C.C.C.C.C.COCOC(=O)CC(=O)NCNC(=O)CC(C)=O Chemical compound C.C.C.C.C.C.COCOC(=O)CC(=O)NCNC(=O)CC(C)=O HPOXOSWBYZBHHP-UHFFFAOYSA-N 0.000 description 1
- PCXROUSMNIAQCC-UHFFFAOYSA-N C.C.C.C.C.C.COCOC(=O)CC(=O)OC(C)C(=O)NCNC(=O)C(C)OC(=O)CC(C)=O Chemical compound C.C.C.C.C.C.COCOC(=O)CC(=O)OC(C)C(=O)NCNC(=O)C(C)OC(=O)CC(C)=O PCXROUSMNIAQCC-UHFFFAOYSA-N 0.000 description 1
- IVEOZYWRUYOXNI-UHFFFAOYSA-N C.C.C.C.C.CCOC(=O)C(CC(C)C)NC.COC(=O)C(CC(C)C)NC(=O)CC(=O)NC(CC(C)C)C(=O)OCOC(=O)C(CC(C)C)NC(=O)CC(C)=O Chemical compound C.C.C.C.C.CCOC(=O)C(CC(C)C)NC.COC(=O)C(CC(C)C)NC(=O)CC(=O)NC(CC(C)C)C(=O)OCOC(=O)C(CC(C)C)NC(=O)CC(C)=O IVEOZYWRUYOXNI-UHFFFAOYSA-N 0.000 description 1
- NXSFWOFIQPTMSY-UHFFFAOYSA-N C.C.C.CCC(=O)CC(=O)NCNC(=O)CC(C)=O Chemical compound C.C.C.CCC(=O)CC(=O)NCNC(=O)CC(C)=O NXSFWOFIQPTMSY-UHFFFAOYSA-N 0.000 description 1
- XCNZQZLWXMDNJA-UHFFFAOYSA-N C.C.C.CCOC(=O)C(C)NC.COC(=O)C(C)NC(=O)CC(=O)NC(C)C(=O)OCOC(=O)C(C)NC(=O)CC(C)=O Chemical compound C.C.C.CCOC(=O)C(C)NC.COC(=O)C(C)NC(=O)CC(=O)NC(C)C(=O)OCOC(=O)C(C)NC(=O)CC(C)=O XCNZQZLWXMDNJA-UHFFFAOYSA-N 0.000 description 1
- MTASMRYGJHUDSK-UHFFFAOYSA-N C.C.CC(=O)C1=CC=C(C(=O)OC(C)C(=O)NCNC(=O)C(C)OC(=O)C2=CC=C(C(=O)OC(C)C)C=C2)C=C1.COC(C)C(=O)CC(C)=O Chemical compound C.C.CC(=O)C1=CC=C(C(=O)OC(C)C(=O)NCNC(=O)C(C)OC(=O)C2=CC=C(C(=O)OC(C)C)C=C2)C=C1.COC(C)C(=O)CC(C)=O MTASMRYGJHUDSK-UHFFFAOYSA-N 0.000 description 1
- RSRICTCUNJLBCQ-UHFFFAOYSA-N C.C.CNC(C)C(=O)OCOC(=O)C(C)NC(=O)CC(C)=O Chemical compound C.C.CNC(C)C(=O)OCOC(=O)C(C)NC(=O)CC(C)=O RSRICTCUNJLBCQ-UHFFFAOYSA-N 0.000 description 1
- KAAQFLWOTTYPOE-UHFFFAOYSA-N C.C.CNC(CC(C)C)C(=O)OCOC(=O)C(CC(C)C)NC(=O)CC(C)=O Chemical compound C.C.CNC(CC(C)C)C(=O)OCOC(=O)C(CC(C)C)NC(=O)CC(C)=O KAAQFLWOTTYPOE-UHFFFAOYSA-N 0.000 description 1
- DESOOJBSFFRTBS-UHFFFAOYSA-N C.CNC(CC(C)C)C(=O)OCOC(=O)C(CC(C)C)NC(=O)C1=CC=C(C(=O)NCC(CC(C)C)O(=O)COC(=O)C(CC(C)C)NC(=O)C2=CC=C(C(C)=O)C=C2)C=C1 Chemical compound C.CNC(CC(C)C)C(=O)OCOC(=O)C(CC(C)C)NC(=O)C1=CC=C(C(=O)NCC(CC(C)C)O(=O)COC(=O)C(CC(C)C)NC(=O)C2=CC=C(C(C)=O)C=C2)C=C1 DESOOJBSFFRTBS-UHFFFAOYSA-N 0.000 description 1
- GRVUCABKSAVUNA-UHFFFAOYSA-N C.CNCNC(=O)CC(=O)NC(CC(C)C)C(=O)OCOC(=O)C(CC(C)C)NC(=O)CC(C)=O Chemical compound C.CNCNC(=O)CC(=O)NC(CC(C)C)C(=O)OCOC(=O)C(CC(C)C)NC(=O)CC(C)=O GRVUCABKSAVUNA-UHFFFAOYSA-N 0.000 description 1
- NNPPMTNAJDCUHE-UHFFFAOYSA-N CC(C)C Chemical compound CC(C)C NNPPMTNAJDCUHE-UHFFFAOYSA-N 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N CC(C)C(N)C(=O)O Chemical compound CC(C)C(N)C(=O)O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N CC(C)CC(N)C(=O)O Chemical compound CC(C)CC(N)C(=O)O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N CC(N)C(=O)O Chemical compound CC(N)C(=O)O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N CC(O)C(=O)O Chemical compound CC(O)C(=O)O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 1
- WHBMMWSBFZVSSR-UHFFFAOYSA-N CC(O)CC(=O)O Chemical compound CC(O)CC(=O)O WHBMMWSBFZVSSR-UHFFFAOYSA-N 0.000 description 1
- QWTDNUCVQCZILF-UHFFFAOYSA-N CCC(C)C Chemical compound CCC(C)C QWTDNUCVQCZILF-UHFFFAOYSA-N 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N CCC(C)C(N)C(=O)O Chemical compound CCC(C)C(N)C(=O)O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- PFEOZHBOMNWTJB-UHFFFAOYSA-N CCC(C)CC Chemical compound CCC(C)CC PFEOZHBOMNWTJB-UHFFFAOYSA-N 0.000 description 1
- REKYPYSUBKSCAT-UHFFFAOYSA-N CCC(O)CC(=O)O Chemical compound CCC(O)CC(=O)O REKYPYSUBKSCAT-UHFFFAOYSA-N 0.000 description 1
- ABIKNKURIGPIRJ-UHFFFAOYSA-N CCC(O)CCC(=O)O Chemical compound CCC(O)CCC(=O)O ABIKNKURIGPIRJ-UHFFFAOYSA-N 0.000 description 1
- AFABGHUZZDYHJO-UHFFFAOYSA-N CCCC(C)C Chemical compound CCCC(C)C AFABGHUZZDYHJO-UHFFFAOYSA-N 0.000 description 1
- JRHWHSJDIILJAT-UHFFFAOYSA-N CCCC(O)C(=O)O Chemical compound CCCC(O)C(=O)O JRHWHSJDIILJAT-UHFFFAOYSA-N 0.000 description 1
- HPMGFDVTYHWBAG-UHFFFAOYSA-N CCCC(O)CC(=O)O Chemical compound CCCC(O)CC(=O)O HPMGFDVTYHWBAG-UHFFFAOYSA-N 0.000 description 1
- GXDHCNNESPLIKD-UHFFFAOYSA-N CCCCC(C)C Chemical compound CCCCC(C)C GXDHCNNESPLIKD-UHFFFAOYSA-N 0.000 description 1
- ZKKJGRNJDPCWCA-UHFFFAOYSA-N CCCCOC(O)C(=O)O Chemical compound CCCCOC(O)C(=O)O ZKKJGRNJDPCWCA-UHFFFAOYSA-N 0.000 description 1
- GRFQEQGWJGULHO-UHFFFAOYSA-N CNC(C)=O.COC(C)=O Chemical compound CNC(C)=O.COC(C)=O GRFQEQGWJGULHO-UHFFFAOYSA-N 0.000 description 1
- OSOQQTKMJZNTEY-UHFFFAOYSA-N CNC(C)C(=O)OCOC(=O)C(C)NC(=O)CC(=O)NC(C)C(=O)OCOC(=O)C(C)NC(=O)CC(C)=O Chemical compound CNC(C)C(=O)OCOC(=O)C(C)NC(=O)CC(=O)NC(C)C(=O)OCOC(=O)C(C)NC(=O)CC(C)=O OSOQQTKMJZNTEY-UHFFFAOYSA-N 0.000 description 1
- FSYSQCBZFWWIRR-UHFFFAOYSA-N CNC(CC(C)C)C(=O)OCOC(=O)C(CC(C)C)NC(=O)CC(=O)NC(CC(C)C)C(=O)OCOC(=O)C(CC(C)C)NC(=O)CC(C)=O Chemical compound CNC(CC(C)C)C(=O)OCOC(=O)C(CC(C)C)NC(=O)CC(=O)NC(CC(C)C)C(=O)OCOC(=O)C(CC(C)C)NC(=O)CC(C)=O FSYSQCBZFWWIRR-UHFFFAOYSA-N 0.000 description 1
- SSIBXOIYLBNHIF-UHFFFAOYSA-N CNC(CC(C)C)C(=O)OCOC(=O)C(CC(C)C)NC(=O)CC(=O)NCNC(=O)CC(C)=O Chemical compound CNC(CC(C)C)C(=O)OCOC(=O)C(CC(C)C)NC(=O)CC(=O)NCNC(=O)CC(C)=O SSIBXOIYLBNHIF-UHFFFAOYSA-N 0.000 description 1
- ZYKJCPATZCHBRQ-UHFFFAOYSA-N CNC(CC(C)C)C(=O)OCOC(=O)C(CC(C)C)NC(=O)CC(=O)OCOC(=O)CC(C)=O Chemical compound CNC(CC(C)C)C(=O)OCOC(=O)C(CC(C)C)NC(=O)CC(=O)OCOC(=O)CC(C)=O ZYKJCPATZCHBRQ-UHFFFAOYSA-N 0.000 description 1
- JQQAAAFTWHQBBS-UHFFFAOYSA-N CNCNC(=O)CC(=O)OCOC(=O)CC(C)=O Chemical compound CNCNC(=O)CC(=O)OCOC(=O)CC(C)=O JQQAAAFTWHQBBS-UHFFFAOYSA-N 0.000 description 1
- FFEARJCKVFRZRR-UHFFFAOYSA-N CSCCC(N)C(=O)O Chemical compound CSCCC(N)C(=O)O FFEARJCKVFRZRR-UHFFFAOYSA-N 0.000 description 1
- ZUEMPYVFHOMJSG-UHFFFAOYSA-N C[NH+]([N][NH+](C)[O-])[O-] Chemical compound C[NH+]([N][NH+](C)[O-])[O-] ZUEMPYVFHOMJSG-UHFFFAOYSA-N 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N NC(=O)CCC(N)C(=O)O Chemical compound NC(=O)CCC(N)C(=O)O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N NC(CC1=CC=CC=C1)C(=O)O Chemical compound NC(CC1=CC=CC=C1)C(=O)O COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- FQPGMQABJNQLLF-UHFFFAOYSA-N NOCCC(N)C(=O)O Chemical compound NOCCC(N)C(=O)O FQPGMQABJNQLLF-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N O=C(O)CC(=O)O Chemical compound O=C(O)CC(=O)O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/08—Materials for coatings
- A61L31/10—Macromolecular materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/04—Macromolecular materials
- A61L31/06—Macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T428/00—Stock material or miscellaneous articles
- Y10T428/31504—Composite [nonstructural laminate]
- Y10T428/31725—Of polyamide
Definitions
- This invention is directed to coatings for drug delivery devices, such as drug eluting vascular stents, and methods for producing the same.
- Percutaneous transluminal coronary angioplasty is a procedure for treating heart disease.
- a catheter assembly having a balloon portion is introduced percutaneously into the cardiovascular system of a patient via the brachial or femoral artery.
- the catheter assembly is advanced through the coronary vasculature until the balloon portion is positioned across the occlusive lesion.
- the balloon is inflated to a predetermined size to radially compress against the atherosclerotic plaque of the lesion to remodel the lumen wall.
- the balloon is then deflated to a smaller profile to allow the catheter to be withdrawn from the patient's vasculature.
- a problem associated with the above procedure includes formation of intimal flaps or torn arterial linings which can collapse and occlude the conduit after the balloon is deflated. Moreover, thrombosis and restenosis of the artery may develop over several months after the procedure, which may require another angioplasty procedure or a surgical by-pass operation. To reduce the partial or total occlusion of the artery by the collapse of arterial lining and to reduce the chance of the development of thrombosis and restenosis, a stent is implanted in the lumen to maintain the vascular patency.
- Stents are used not only as a mechanical intervention but also as a vehicle for providing biological therapy.
- stents act as scaffoldings, functioning to physically hold open and, if desired, to expand the wall of the passageway.
- stents are capable of being compressed, so that they can be inserted through small vessels via catheters, and then expanded to a larger diameter once they are at the desired location. Examples in patent literature disclosing stents which have been applied in PTCA procedures include stents illustrated in U.S. Pat. No. 4,733,665 issued to Palmaz, U.S. Pat. No. 4,800,882 issued to Gianturco, and U.S. Pat. No. 4,886,062 issued to Wiktor.
- Biological therapy can be achieved by medicating the stents.
- Medicated stents provide for the local administration of a therapeutic substance at the diseased site. In order to provide an efficacious concentration to the treated site, systemic administration of such medication often produces adverse or toxic side effects for the patient. Local delivery is a preferred method of treatment in that smaller total levels of medication are administered in comparison to systemic dosages, but are concentrated at a specific site. Local delivery thus produces fewer side effects and achieves more favorable results.
- One proposed method for medicating stents involves the use of a polymeric carrier coated onto the surface of a stent. A solution which includes a solvent, a polymer dissolved in the solvent, and a therapeutic substance dispersed in the blend is applied to the stent. The solvent is allowed to evaporate, leaving on the stent surface a coating of the polymer and the therapeutic substance impregnated in the polymer.
- One polymer that can be used for making stent coatings for local drug delivery can be selected from a group of poly(ester amides) described in U.S. Pat. No. 6,503,538 to Chu et al.
- some mechanical properties, such as hardness of the poly(ester amides) taught by Chu et al. may be insufficiently good for stent applications. Accordingly, there is a need to have poly(ester amides) with better properties to allow the poly(ester amides) to be used to make stent coatings for local drug delivery.
- a medical article comprising an implantable substrate having a coating, the coating includes a polymeric product of a reaction between a first reagent, a second reagent, and a third reagent, wherein: (a) the first reagent can be one of the compounds having formulae (1), (2), (3), and (4);
- the second reagent can be one of the compounds having formulae (5), (6), (7), and (8);
- the third reagent can be a dicarboxylic acid having the formula (9):
- R 1 can be hydrogen, methyl, iso-propyl, sec-butyl; iso-butyl, or benzyl group
- R 2 can be methylene, methylmethylene, n-propylene, iso-propylene, ethylmethylene, n-butylene, iso-butylene, sec-butylene, or n-amylene group
- R 3 can be a straight chained or branched aliphatic alkylene group C n H 2n , wherein n is an integer between 2 and 12
- R 4 can be a moiety derived from a compound selected from a group consisting of poly(ethylene glycol), poly(propylene glycol), random poly(ethylene glycol-co-propylene glycol), poly(ethylene glycol)-block-poly(propylene glycol), hyaluronic acid, poly(2-hydroxyethyl methacrylate), poly(3-hydroxypropylmethacrylamide), poly(
- a medical article comprising an implantable substrate having a coating, and the coating includes a copolymer having a general formula (10) or (11):
- M can be a moiety represented by the structure having the formula (12);
- P can be one of the moieties having the formulae (13), (14), (15), and (16);
- Q can be one of the moieties having the formulae (17), (18), and (19);
- M 1 can be a moiety represented by the formula (20);
- R 1 can be hydrogen, methyl, iso-propyl, sec-butyl; iso-butyl, or benzyl group
- R 2 can be methylene, methylmethylene, n-propylene, iso-propylene, ethylmethylene, n-butylene, iso-butylene, sec-butylene, or n-amylene group
- R 3 can be a straight chained or branched aliphatic alkylene group C n H 2n , wherein n is an integer between 2 and 12
- X can be a straight chained or branched aliphatic alkylene group C n H 2n , wherein n is an integer between 2 and 12
- Y can be a straight chained or branched aliphatic alkylene group C n H 2n , wherein n is 1, 2, or 5
- Z can be a moiety derived from a compound selected from a group consisting of poly
- a method for fabricating a medical article includes synthesizing a copolymer and forming a coating based on the copolymer on at least a portion of an implantable substrate, the synthesizing of the copolymer including reacting a first reagent with a second reagent and with a third reagent, wherein: (a) the first reagent can be one of the compounds having formulae (1), (2), (3), and (4); (b) the second reagent can be one of the compounds having formulae (5), (6), (7), and (8); and (c) the third reagent is a dicarboxylic acid having the formula (9), where the formulae (1)-(9) are provided above.
- a method for fabricating a medical article including synthesizing a copolymer and forming a coating based on the copolymer on at least a portion of an implantable substrate, wherein the copolymer has a general formula (10) or (11), where the formulae (10) and (11) are provided above.
- biologically absorbable coatings and/or polymers is defined as coatings and/or polymers that are capable of being completely degraded and/or eroded when exposed to bodily fluids such as blood and are gradually resorbed, absorbed and/or eliminated by the body.
- the processes of breaking down and eventual absorption and elimination of the coating and/or polymer can be caused, for example, by hydrolysis, metabolic processes, bulk or surface erosion, and the like.
- stent coatings and/or polymers forming such stent coatings are considered “biologically absorbable” if the coatings and/or polymers are substantially broken down by the in vivo environment, or by the in vitro environment, such as one having physical, chemical, and/or biological characteristics substantially similar to those of the in vivo environment.
- An amount of time needed to break down the coatings and/or polymers can be between about 1 day and several years, or between about 1 day and about 24 months; alternatively, between about 2 months and about 18 months; alternatively, between about 3 month and about 12 months.
- substantially broken down means that a substantial reduction of the molecular weight of a polymer occurs as a result of the exposure of the polymer to the in vivo environment or to a simulated in vivo environment.
- the simulated in vivo environment can be the in vitro environment having physical, chemical, and/or biological characteristics that are identical or substantially similar to those of the in vivo environment.
- Standard analytical techniques normally used by those having ordinary skill in the art can be used to monitor the change of the molecular weight of the polymer.
- One analytical technique that can be used includes immersing the polymer in a simulated in vivo environment and measuring the loss of the molecular weight of the polymer over time.
- a number of methods can be used for measuring the molecular weight, for example, gel permeation chromatography (GPC).
- GPC gel permeation chromatography
- the polymer if the polymer has lost more than about 10% of its original molecular weight over a 3-month period, then it can be classified as biodegradable.
- poly(ester amide) or “PEA” is defined as a polymer having both at least one ester bond (I) and at least one amide bond (II):
- a coating for an implantable medical device such as a stent, according to embodiments of the present invention, can be a multi-layer structure that can include the following three layers:
- a drug-polymer layer also referred to as “reservoir” or “reservoir layer”
- a drug-polymer layer comprising a polymer and a drug, or alternatively a polymer free drug layer
- Each layer of the stent coating can be formed on the stent by dissolving a polymer or a blend of polymers in a solvent, or a mixture of solvents, and applying the resulting polymer solution on the stent by spraying or immersing the stent in the solution. After the solution has been applied onto the stent, the coating is dried by allowing the solvent to evaporate. The process of drying can be accelerated if the drying is conducted at an elevated temperature.
- the drug can be combined with the polymer solution that is applied onto the stent as described above.
- the drug can be dissolved in a suitable solvent or mixture of solvents, and the resulting drug solution can be applied on the stent by spraying or immersing the stent in the drug solution.
- the drug can be introduced as a colloid system, such as a suspension in an appropriate solvent phase.
- the drug can be dispersed in the solvent phase using conventional techniques used in colloid chemistry.
- solvent to form the solvent phase of the suspension, as well as the quantity of the drug to be dispersed in the solvent phase.
- the suspension can be mixed with a polymer solution and the mixture can be applied on the stent as described above. Alternatively, the drug suspension can be applied on the stent without being mixed with the polymer solution.
- the drug-polymer layer can be applied directly onto at least a part of the stent surface to serve as a reservoir for at least one active agent or a drug which is incorporated into the reservoir layer.
- the optional primer layer can be applied between the stent and the reservoir to improve the adhesion of the drug-polymer layer to the stent.
- the optional topcoat layer can be applied over at least a portion of the reservoir layer and to serve as a rate limiting membrane which helps to control the rate of release of the drug.
- the topcoat layer can be essentially free from any active agents or drugs.
- any or all of the layers of the stent coating can be made of a polymer that is both biologically beneficial and biologically degradable, erodable, absorbable, and/or resorbable.
- just the outermost layer of the coating can be limited to such a polymer.
- the outermost layer is the topcoat layer, which is made of a biologically absorbable block copolymer.
- the remaining layers i.e., the primer and the reservoir layer
- the block copolymer can be the same or different in each layer.
- the stent coating can have only two layers: the optional primer and the reservoir.
- the reservoir in this case is the outermost layer of the stent coating and is made of a biologically absorbable block copolymer.
- the primer can be also fabricated of a biologically absorbable block copolymer, which can be the same or different in the reservoir and in the primer.
- the biologically absorbable copolymers that can be used for making any of the stent coating layers include poly(ester amides) (PEA).
- PDA poly(ester amides)
- condensation copolymers such as poly(esters) having no amide bonds, can be used instead of PEAs.
- the PEAs are products of reaction between at least one reagent from group A, at least one reagent from group B and a reagent C 1 from group C.
- the poly(esters) are products of reaction between at least one reagent from group A and a reagent C 2 from group C.
- the precursor-reagents from groups A, B, and C that can be used are characterized as follows.
- the group A precursor-reagents (hereinafter, “reagents”) that can be used for synthesizing the biologically absorbable copolymers according to embodiments of the present invention are summarized in Table 1.
- the definition used to describe a chemical family to which each of the group A reagents belongs is also provided in Table 1.
- R 1 — (a) hydrogen
- R 2 — (a) methylene (—CH 2 —);
- X straight chained or branched aliphatic alkylene group C 1 H 2n , wherein n is an integer between 2 and 16, e.g., methylene, ethylene, propylene, butylene, amylene (pentylene), hexylene, heptylene, octylene, nonylene, decylene, undecylene, or dodecylene group; and
- Y straight chained or branched aliphatic alkylene group C 2 H 4 (ethylene), C 3 H 6 (propylene), C 4 H 8 (butylene), or C 5 H 10 (pentylene also known as amylene).
- the reagent A 1 is a diol-diamine that can be synthesized by condensation of two molar equivalents of an amino acid and one molar equivalent of a diol.
- the synthesis can be carried under the conditions favoring esterification of the amino acid via the amino acid's carboxyl group.
- the reaction can be conducted under dehydrating conditions which include anhydrous environment and an elevated temperature, for example, about 50° C., and can be catalyzed by a strong acid or base, e.g., p-toluenesulfonic acid.
- the diol that can be used to make the reagent A 1 has the formula HO—X—OH, where X is as defined above.
- Representative examples of diols that can be used include ethylene glycol, 1,3-propanediol, 1,4-butane diol, 1,5-pentanediol, 1,6-hexanediol, 1,7-heptanediol, 1,8-octanediol, 1,9-nonanediol, 1,10-decanediol, 1,11-undecanediol, and 1,12-dodecanediol.
- the amino acid that can be used to make the reagent A 1 has the formula H 2 N—CHR 1 —COOH, where R 1 is as defined above.
- amino acids listed in Table 2 alternatively other amino acids can be used.
- One example of such alternative amino acids is proline (2-pyrrolidine carboxylic acid).
- Other alternative amino acids that can be used include some amino acids having free hydroxyl groups or second carboxyl groups if the free hydroxyl groups or the second carboxyl groups are protected first. The protection is needed so as to avoid interference when reagent A 1 is subsequently reacted with reagents of groups B and C, as discussed above. Examples of the amino acids that can be used after the free hydroxyl or second carboxyl groups are protected include tyrosine, serine, or glutamic acid.
- the reagent A 2 is an amidediol that can be synthesized by condensation of two molar equivalents of a hydroxy acid and one molar equivalent of a diamine.
- the synthesis can be carried under the conditions favoring formation of an amide bond.
- the reaction can be conducted under dehydrating conditions, which include anhydrous environment and can be catalyzed by a strong base. Simple heating of the neat starting materials with the simultaneous removal of generated water by distillation can also be used.
- the diamine that can be used to make the reagent A 2 has the formula H 2 N—Y—NH 2 , where Y is as defined above. Accordingly, examples of diamines that can be used include 1,4-butanediamine (putrescine) (Y ⁇ CH 2 CH 2 CH 2 CH 2 ). Alternatively, other diamines, such as 1,2-ethanediamine (Y ⁇ CH 2 CH 2 ) or 1,5-pentanediamine (cadavarene) (Y ⁇ CH 2 CH 2 CH 2 CH 2 CH 2 ) can be used.
- the hydroxy acid that can be used to make the reagent A 2 has the formula HO—R 2 —COOH, where R 2 is as defined above.
- the reagent A 3 is a common simple diol having the formula HO—X—OH, where X is as defined above; and the reagent A 4 is a common simple diamine having the formula H 2 N—Y—NH 2 , where Y is as defined above.
- the group B reagents that can be used for synthesizing the biologically absorbable copolymers according to embodiments of the present invention are summarized in Table 4. Exemplary definitions used to describe a chemical family to which each of the group B reagents belongs is also provided in Table 4.
- R 4 is a moiety derived from poly(ethylene glycol) (PEG).
- PEG poly(ethylene glycol)
- R 4 other biologically beneficial moieties can be used as R 4 , for example, moieties derived from poly(propylene glycol) (PPG), random or block copolymers of PEG and PPG, hyaluronic acid, poly(2-hydroxyethylmethacrylate), poly(3-hydroxypropylmethacrylamide), or cellulosics.
- the synthesis can be carried under the conditions favoring esterification of the amino acid via the carboxyl group.
- the reaction can be conducted under dehydrating conditions which include anhydrous environment and an elevated temperature, for example, about 50° C., and can be catalyzed by a strong acid or base, e.g., p-toluenesulfonic acid.
- PEG having molecular weight between about 100 and 4,000 Daltons, for example, about 300 Daltons, can be used.
- amino acid listed in Table 2 can be used.
- other amino acids can be used, for example, tyrosine, serine, or glutamic acid, if free hydroxyl groups of tyrosine and serine or the second carboxyl group of glutamic acid are protected so as not to interfere when reagent B 1 is subsequently reacted with reagents of groups A and C, as discussed above.
- the reagent B 2 can be a PEG-amidediol that can be synthesized by condensation of two molar equivalents of a hydroxy acid and one molar equivalent of a PEG-diamine.
- the synthesis can be carried under the conditions favoring formation of an amide bond.
- the reaction can be conducted under dehydrating conditions which include anhydrous environment, and can be catalyzed by a strong base, or prepared from neat reagents by heating at high temperature with the simultaneous removal of generated water, e.g., the removal of water by distillation. Any hydroxy acid listed in Table 3 can be used.
- PEG terminated with amino groups on both ends (PEG-diamine reagent B 4 ) can be obtained from Huntsman Chemical Co. of Houston, Tex. under the trade name JEFFAMINE.
- the group C reagents that can be used for synthesizing the biologically absorbable copolymers according to embodiments of the present invention are summarized in Table 5.
- the definition used to describe a chemical family to which each of the group C reagents belongs is also provided in Table 5.
- dicarboxylic acids that can be used as the reagent C 1 are summarized in Table 6.
- Dicarboxylic Acid that Can Be Used As The Reagent C 1 Dicarboxylic Acid (HOOC—R 3 —COOH) No. R 3 Formula Name 1 —(CH 2 ) 2 — HOOC—(CH 2 ) 2 —COOH succinic (butanedioic) acid 2 —(CH 2 ) 4 — HOOC—(CH 2 ) 4 —COOH adipic (hexanedioic) acid 3 —(CH 2 ) 8 — HOOC—(CH 2 ) 8 —COOH sebacic (decanedioic) acid 4 (p)-C 6 H 4 — HOOC-(p)C 6 H 4 —COOH terephthalic (1,4- benzene dicarboxylic) acid
- reagents of groups A, B, and C may themselves contain hydrolysable bonds, i.e. ester or amide bonds. These reagents can be then polymerized, the polymerization creating additional bonds that may be both ester and amide bonds, only amide bonds, or only ester bonds. Given that the reagents can be obtained separately, the types of polymers formed during the polymerization can belong to one of the following four categories (A), (B), (C), or (D):
- M is a moiety represented by the structure
- P is a moiety including
- Q is a moiety selected from a group consisting of
- M 1 is a moiety represented by the structure
- R 1 , R 2 , R 3 , X and Y are substitutents and moieties as defined above;
- Z is a moiety that can be derived from a compound selected from a group consisting of poly(ethylene glycol)(PEG), poly(propylene glycol) (PPG), random or block copolymers of PEG and PPG, hyaluronic acid, poly(2-hydroxyethylmethacrylate), poly(3-hydroxypropyl methacrylamide), poly(styrene sulfonate), poly(vinyl pyrrolidone), and cellulosics; and
- n, and p are integers where the value of m can be between 5 and 1,800, the value of n can be between 1 and 800 and the value of p can be between 4 and 1,500.
- Any layer of the stent coating can contain any amount of the biologically absorbable copolymers described above, or a blend of more than one of such copolymers. If less than 100% of the layer is made of the biologically absorbable copolymers, or blends thereof, described above, alternative polymers can comprise the balance.
- polyacrylates such as poly(butyl methacrylate), poly(ethyl methacrylate), and poly(ethyl methacrylate-co-butyl methacrylate)
- fluorinated polymers and/or copolymers such as poly(vinylidene fluoride) and poly(vinylidene fluoride-co-hexafluoropropene), poly(N-vinyl pyrrolidone), poly(hydroxyvalerate), poly(L-lactic acid), polycaprolactone, poly(lactide-co-glycolide), poly(hydroxybutyrate), poly(hydroxybutyrate-co-valerate), polydioxanone, polyorthoester, polyanhydride, poly(glycolic acid), poly(D,L-lactic acid), poly(glycolic acid-co-trimethylene carbonate), polyphosphoester, polyphosphoester urethane, poly(amino acids), cyan
- solvents suitable for making the stent coatings include N,N-dimethylacetamide (DMAC), N,N-dimethylformamide (DMF), tethrahydrofurane (THF), cyclohexanone, xylene, toluene, acetone, i-propanol, methyl ethyl ketone, propylene glycol monomethyl ether, methyl butyl ketone, ethyl acetate, n-butyl acetate, and dioxane.
- DMAC N,N-dimethylacetamide
- DMF N,N-dimethylformamide
- THF tethrahydrofurane
- cyclohexanone cyclohexanone
- xylene toluene
- acetone i-propanol
- methyl ethyl ketone propylene glycol monomethyl ether
- butyl ketone eth
- FLUX REMOVER AMS is trade name of a solvent manufactured by Tech Spray, Inc. of Amarillo, Tex. comprising about 93.7% of a mixture of 3,3-dichloro-1,1,1,2,2-pentafluoropropane and 1,3-dichloro-1,1,2,2,3-pentafluoropropane, and the balance of methanol, with trace amounts of nitromethane.
- solvent or a mixture of solvents suitable for a particular polymer being dissolved are examples of a solvent manufactured by Tech Spray, Inc. of Amarillo, Tex. comprising about 93.7% of a mixture of 3,3-dichloro-1,1,1,2,2-pentafluoropropane and 1,3-dichloro-1,1,2,2,3-pentafluoropropane, and the balance of methanol, with trace amounts of nitromethane.
- Those having ordinary skill in the art will select the solvent or a mixture of solvents suitable for a particular poly
- the therapeutic substance which can be used in the reservoir layer can include any substance capable of exerting a therapeutic or prophylactic effect for a patient.
- the therapeutic substance may include small molecule substances, peptides, proteins, oligonucleotides, and the like.
- the therapeutic substance could be designed, for example, to inhibit the activity of vascular smooth muscle cells. It can be directed at inhibiting abnormal or inappropriate migration and/or proliferation of smooth muscle cells to inhibit restenosis.
- therapeutic substances examples include antiproliferative substances such as actinomycin D, or derivatives and analogs thereof (manufactured by Sigma-Aldrich of Milwaukee, Wis., or COSMEGEN available from Merck). Synonyms of actinomycin D include dactinomycin, actinomycin IV, actinomycin I 1 , actinomycin X 1 , and actinomycin C 1 .
- the active agent can also fall under the genus of antineoplastic, anti-inflammatory, antiplatelet, anticoagulant, antifibrin, antithrombin, antimitotic, antibiotic, antiallergic and antioxidant substances. Examples of such antineoplastics and/or antimitotics include paclitaxel (e.g.
- TAXOL® by Bristol-Myers Squibb Co., Stamford, Conn.
- docetaxel e.g. Taxotere®, from Aventis S.A., Frankfurt, Germany
- methotrexate azathioprine
- vincristine vincristine
- vinblastine a cell line
- fluorouracil a cell line
- doxorubicin hydrochloride e.g. Adriamycin® from Pharmacia & Upjohn, Peapack N.J.
- mitomycin e.g. Mutamycin® from Bristol-Myers Squibb Co., Stamford, Conn.
- antiplatelets examples include sodium heparin, low molecular weight heparins, heparinoids, hirudin, argatroban, forskolin, vapiprost, prostacyclin and prostacyclin analogues, dextran, D-phe-pro-arg-chloromethylketone (synthetic antithrombin), dipyridamole, glycoprotein IIb/IIIa platelet membrane receptor antagonist antibody, recombinant hirudin, and thrombin inhibitors such as ANGIOMAX (Biogen, Inc., Cambridge, Mass.).
- cytostatic or antiproliferative agents examples include angiopeptin, angiotensin converting enzyme inhibitors such as captopril (e.g. Capoten® and Capozide® from Bristol-Myers Squibb Co., Stamford, Conn.), cilazapril or lisinopril (e.g.
- calcium channel blockers such as nifedipine), colchicine, fibroblast growth factor (FGF) antagonists, fish oil (omega 3-fatty acid), histamine antagonists, lovastatin (an inhibitor of HMG-CoA reductase, a cholesterol lowering drug, brand name Mevacor® from Merck & Co., Inc., Whitehouse Station, N.J.), monoclonal antibodies (such as those specific for Platelet-Derived Growth Factor (PDGF) receptors), nitroprusside, phosphodiesterase inhibitors, prostaglandin inhibitors, suramin, serotonin blockers, steroids, thioprotease inhibitors, triazolopyrimidine (a PDGF antagonist), and nitric oxide.
- PDGF Platelet-Derived Growth Factor
- an antiallergic agent is permirolast potassium.
- Other therapeutic substances or agents which may be appropriate include alpha-interferon, genetically engineered epithelial cells, tacrolimus, dexamethasone, and rapamycin and structural derivatives or functional analogs thereof, such as 40-O-(2-hydroxy)ethyl-rapamycin (known by the trade name of EVEROLIMUS available from Novartis), 40-O-(3-hydroxy)propyl-rapamycin, 40-O-[2-(2-hydroxy)ethoxy]ethyl-rapamycin, and 40-O-tetrazole-rapamycin.
- a stent e.g., a balloon expandable or self-expandable stent.
- the use of the coating is not limited to stents, and the coating can also be used with a variety of other medical devices, such as implantable medical devices.
- implantable medical device examples include stent-grafts, grafts (e.g., aortic grafts), catheters, guidewires, artificial heart valves, cerebrospinal fluid shunts, pacemaker electrodes, axius coronary shunts and endocardial leads (e.g., FINELINE and ENDOTAK, available from Guidant Corporation).
- grafts e.g., aortic grafts
- catheters e.g., guidewires, artificial heart valves, cerebrospinal fluid shunts, pacemaker electrodes, axius coronary shunts and endocardial leads (e.g., FINELINE and ENDOTAK, available from Guidant Corporation).
- endocardial leads e.g., FINELINE and ENDOTAK, available from Guidant Corporation.
- the underlying structure of the device can be of virtually any design.
- the device can be made of a metallic material or an alloy such as, but not limited to, cobalt-chromium alloys (e.g., ELGILOY), stainless steel (316L), “MP35N,” “MP20N,” ELASTINITE (Nitinol), tantalum, tantalum-based alloys, nickel-titanium alloy, platinum, platinum-based alloys such as, e.g., platinum-iridium alloy, iridium, gold, magnesium, titanium, titanium-based alloys, zirconium-based alloys, or combinations thereof.
- Devices made from bioabsorbable or biostable polymers can also be used with the embodiments of the present invention.
- MP35N and MP20N are trade names for alloys of cobalt, nickel, chromium and molybdenum available from Standard Press Steel Co. of Jenkintown, Pa. “MP35N” consists of 35% cobalt, 35% nickel, 20% chromium, and 10% molybdenum. “MP20N” consists of 50% cobalt, 20% nickel, 20% chromium, and 10% molybdenum.
- Medical devices can be also made from the materials of the invention.
- the polymers can be used for a variety of medical applications, including particles for drug delivery to embolize blood vessels.
- the polymers of the present invention can have a variety of medical applications, including the treatment of stenosis, restenosis, and cancer.
- a copolymer having formula (III) can be synthesized and used in practice of the invention.
- the copolymer (III) is a product of copolymerization of reagents A 1 , B 1 , and C 1 .
- a 1 can be a diol-diamine shown in Table 1 where R 1 is i-C 4 H 9 and X is (CH 2 ) 6 .
- a 1 can be synthesized by condensation of leucine with 1,6-hexanediol.
- B 1 can be a PEG-diester-diamine shown in Table 4 where R 1 is i-C 4 H 9 and PEG 300 symbolizes a moiety derived from poly(ethylene glycol) having molecular weight of about 300 Daltons.
- B 1 can be synthesized by condensation of leucine with poly(ethylene glycol) having molecular weight of about 300 Daltons.
- C 1 can be a dicarboxylic acid shown in Table 5 where R 3 is (CH 2 ) 8 (sebacic acid, which is also shown in Table 6).
- the mixture can be stirred until full dissolution and then the temperature can be raised to about 80° C. After stirring for about 24 hours, the viscous mixture can be cooled to room temperature, diluted with about 100 ml ethanol, and precipitated into an excess of water. The separated polymer can be thoroughly washed with water, spread thinly onto a TEFLON pan, and dried at room temperature under vacuum (about 70 mm Hg) for about 24 hours.
- a copolymer having formula (IV) can be synthesized and used in practice of the invention.
- the copolymer (IV) is a product of copolymerization of reagents A 1 , B 1 , and C 1 .
- a 1 can be a diol-diamine shown in Table 1, where R 1 is CH 3 and X is (CH 2 ) 4 .
- a 1 can be synthesized by condensation of alanine with 1,4-butanediol.
- B 1 can be a PEG-diester-diamine shown in Table 4 where R 1 is i-C 4 H 9 and PEG 300 symbolizes a moiety derived from poly(ethylene glycol) having molecular weight of about 300 Daltons.
- B 1 can be synthesized by condensation of alanine with poly(ethylene glycol) having molecular weight of about 300 Daltons.
- C 1 can be a dicarboxylic acid shown in Table 5 where R 3 is (CH 2 ) 2 (succinic acid, which is also shown in Table 6).
- the mixture can be stirred until full dissolution and then the temperature can be raised to about 80° C. After stirring for about 24 hours, the viscous mixture can be cooled to room temperature, diluted with about 100 ml ethanol, and precipitated into an excess of water. The separated polymer is thoroughly washed with water, spread thinly into a TEFLON pan, and dried at room temperature under vacuum (about 70 mm Hg) for about 24 hours.
- a copolymer having formula (V) can be synthesized and used in practice of the invention.
- the copolymer (V) is a product of copolymerization of reagents A 1 , B 1 , and C 1 .
- a 1 can be a diol-diamine shown in Table 1 where R 1 is i-C 4 H 9 and X is (CH 2 ) 4 .
- a 1 can be synthesized by condensation of leucine with 1,4-butanediol.
- B 1 can be a PEG-diester-diamine shown in Table 4 where R 1 is i-C 4 H 9 and PEG 300 symbolizes a moiety derived from poly(ethylene glycol) having molecular weight of about 300 Daltons.
- B 1 can be synthesized by condensation of leucine with poly(ethylene glycol) having molecular weight of about 300 Daltons.
- C 1 can be a dicarboxylic acid shown in Table 5 where R 3 is para-C 6 H 4 (terephthalic acid, which is also shown in Table 6).
- the copolymer (V) can be obtained using the same synthetic technique as described in Example 2 for copolymer (IV), except di-para-nitrophenyl terephthalate can be used to make the copolymer (V), instead of di-para-nitrophenyl succinate.
- a copolymer having formula (VI) can be synthesized and used in practice of the invention.
- the copolymer (VI) is a product of copolymerization of reagents A 1 , B 2 , and C 1 .
- a 1 can be a diol-diamine shown in Table 1 where R 1 is i-C 4 H 9 and X is (CH 2 ) 6 .
- a 1 can be synthesized by condensation of leucine with 1,6-hexanediol.
- B 2 can be a PEG-amidediol shown in Table 4 where R 2 is methylmethylene CH(CH 3 ).
- B 2 can be synthesized by condensation of lactic acid with PEG-diamine shown as reagent B 4 in Table 4.
- PEG-diamine can be based on poly(ethylene glycol) having molecular weight of about 600 Daltons, which is symbolized by the abbreviation PEG 600 .
- JEFFAMINE ED-600 available from Huntsman Corp. can be used.
- JEFFAMINE ED-600 is a trade name of O,O′-bis-[(2-aminopropyl) poly(propylene glycol)-block-poly(ethylene glycol)-block-poly(propylene glycol)], which is a polyether diamine with a polyalkylene oxide backbone.
- the molecular weight of JEFFAMINE ED-600 is about 600 Daltons.
- C 1 can be a dicarboxylic acid shown in Table 5 where R 3 is (CH 2 ) 8 (sebacic acid, which is also shown in Table 6).
- R 3 is (CH 2 ) 8 (sebacic acid, which is also shown in Table 6).
- a copolymer having formula (VII) can be synthesized and used in practice of the invention.
- the copolymer (VII) can be synthesized in same way as the copolymer (VI) of Example 4, except instead of a reagent B 2 (e.g., PEG-amidediol), reagent B 4 (e.g., PEG-diamine) shown in Table 4 can be used.
- reagent B 2 e.g., PEG-amidediol
- reagent B 4 e.g., PEG-diamine
- a copolymer having formula (VIII) can be synthesized and used in practice of the invention.
- the copolymer (VIII) is a product of copolymerization of reagents A 2 , B 1 , and C 1 .
- a 2 can be an amidediol shown in Table 1 where R 2 is methylmethylene CH(CH 3 ) and Y is (CH 2 ) 4 .
- a 2 can be synthesized by condensation of lactic acid with the 1,4-diamino butane (putrescine).
- B 1 can be a PEG-diester-diamine shown in Table 4 where R 1 is i-C 4 H 9 .
- B 1 can be synthesized by condensation of leucine with poly(ethylene glycol) having molecular weight of about 2,000 Daltons, which is symbolized by the abbreviation PEG 2000 .
- C 1 can be a dicarboxylic acid shown in Table 5 where R 3 is (CH 2 ) 8 (sebacic acid, which is also shown in Table 6).
- R 3 is (CH 2 ) 8 (sebacic acid, which is also shown in Table 6).
- a copolymer having formula (IX) can be synthesized and used in practice of the invention.
- the copolymer (IX) can be synthesized in same way as the copolymer (VIII) of Example 6, except instead of a reagent B 1 (PEG-diester-diamine), reagent B 2 (PEG-amidediol) shown in Table 4 can be used, where R 2 is methylmethylene CH(CH 3 ).
- B 2 can be synthesized by condensation of lactic acid with PEG-diamine shown as reagent B 4 in Table 4.
- PEG-diamine can be based on poly(ethylene glycol) having molecular weight of about 600 Daltons, which is symbolized by the abbreviation PEG 600 .
- a copolymer having formula (X) can be synthesized and used in practice of the invention.
- the copolymer (X) can be synthesized in same way as the copolymer (IX) of Example 7, except that a reagent B 3 shown in Table 4, (HO—R 4 —OH), for example, PEG-diol, can be used instead of a reagent B 2 (e.g., PEG-amidediol).
- PEG-diol can be based on poly(ethylene glycol) having molecular weight of about 300 Daltons, which is symbolized by the abbreviation PEG 300 .
- a 2 and B 3 reagents can be combined and reacted first to form an A 2 -B 3 moiety, followed by adding a C 1 reagent and completing polycondensation.
- the conditions for the synthesis can be determined by those having ordinary skill in the art.
- the final step of the reaction (reacting C 1 with the A 2 -B 3 moiety) can be conducted in the presence of a coupling agent such as carbodiimide.
- a dichloride of the diacid can be used, for instance, sebacyl dichloride.
- copolymer (X) can be also synthesized to make the copolymer (X) harder.
- an amino acid with shorter R 2 group or a shorter chain diamine e.g., ethanediamine instead of 1,4-butanediamine
- a shorter chain diamine e.g., ethanediamine instead of 1,4-butanediamine
- a copolymer having formula (XI) can be synthesized and used in practice of the invention.
- the copolymer (XI) can be synthesized in same way as the copolymer (X) of Example 9, except that a reagent B 4 (such as PEG-diamine) shown in Table 4 can be used instead of a reagent B 3 (e.g., PEG-diol).
- PEG-diamine can be based on poly(ethylene glycol) having molecular weight of about 600 Daltons, which is symbolized by the abbreviation PEG 600 .
- a copolymer having formula (XII) can be synthesized and used in practice of the invention.
- the copolymer (XII) can be synthesized in same way as the copolymer (VIII) of Example 6, except that a reagent A 3 (diol) shown in Table 1 can be used instead of a reagent A 2 (amidediol), where X is (CH 2 ) 6 . In other words, 1,6-hexanediol can be used as the reagent A 3 .
- a poly(ethylene glycol) moiety having molecular weight of about 300 Daltons can comprise a part of copolymer (XII), which is symbolized by the abbreviation PEG 300 .
- a copolymer having formula (XIII) can be synthesized and used in practice of the invention.
- the copolymer (XIII) can be synthesized in same way as the copolymer (XII) of Example 10, except that a reagent B 2 (e.g., PEG-amidediol) shown in Table 4 can be used instead of a reagent B 1 (such as PEG-diester-diamine), where R 2 is methylmethylene CH(CH 3 ).
- B 2 can be synthesized by condensation of lactic acid with PEG-diamine shown as reagent B 4 in Table 4.
- PEG-diamine can be based on poly(ethylene glycol) having molecular weight of about 600 Daltons, which is symbolized by the abbreviation PEG 600 .
- a copolymer having formula (XIV) can be synthesized and used in practice of the invention.
- the copolymer (XIV) can be synthesized in same way as the copolymer (XIII) of Example 11, except that a reagent B 4 (e.g., PEG-diamine) as shown in Table 4 can be used instead of a reagent B 2 (such as PEG-amidediol).
- PEG-diamine can be based on poly(ethylene glycol) having molecular weight between about 300 and about 2,400 Daltons, for example, about 600 Daltons, which is symbolized by the abbreviation PEG 600 .
- Reagent A 3 (1,6-hexanediol) and reagent C 1 (sebacic acid) can be combined and reacted first to form an A 3 -C 1 moiety, followed by adding reagent B 4 and completing polycondensation.
- reagent B 4 a compound that can be used as the C 1 reagent instead of sebacic acid.
- the conditions for the synthesis can be determined by those having ordinary skill in the art.
- a copolymer having formula (XV) can be synthesized and used in practice of the invention.
- the copolymer (XV) can be synthesized in same way as the copolymer (VIII) of Example 6, except that a reagent A 4 (diamine) shown in Table 1 can be used instead of a reagent A 2 (amidediol), where Y is (CH 2 ) 4 .
- putrescine can be used as the reagent A 4 .
- a poly(ethylene glycol) moiety having molecular weight between about 300 Daltons and about 4,000 Daltons, for example, about 300 Daltons, can comprise a part of copolymer (XV), which is symbolized by the abbreviation PEG 300 .
- a copolymer having formula (XVI) can be synthesized and used in practice of the invention.
- the copolymer (XVI) can be synthesized in same way as the copolymer (IX) of Example 7, except that a reagent A 4 (diamine) shown in Table 1 can be used instead of a reagent A 2 (amidediol), where Y is (CH 2 ) 4 . In other words, putrescine can be used as the reagent A 4 .
- a poly(ethylene glycol) moiety having molecular weight between about 300 Daltons and about 4,000 Daltons, for example, about 600 Daltons, can comprise a part of copolymer (XVI), which is symbolized by the abbreviation PEG 600 .
- n can be between about 98 and about 77
- a copolymer having formula (XVII) can be synthesized and used in practice of the invention.
- the copolymer (XVII) can be synthesized in same way as the copolymer (X) of Example 8, except that a reagent A 4 (diamine) shown in Table 1 can be used instead of a reagent A 2 (amidediol), where Y is (CH 2 ) 4 . In other words, putrescine can be used as the reagent A 4 .
- a poly(ethylene glycol) moiety having molecular weight between about 300 Daltons and about 4,000 Daltons, for example, about 2,000 Daltons can comprise a part of copolymer (XVII), which is symbolized by the abbreviation PEG 2000 .
- a copolymer having formula (XVIII) can be synthesized and used in practice of the invention.
- a 1 can be a diol-diamine shown in Table 1, where R 1 is i-C 4 H 9 and X is (CH 2 ) 6 .
- a 1 can be synthesized by condensation of leucine with 1,6-hexanediol.
- C 2 can be a PEG-dicarboxylic acid shown in Table 5, derived from poly(ethylene glycol) having molecular weight of about 1,000 Daltons, which is symbolized by the abbreviation PEG 1000 .
- a total molecular weight of the copolymer (XVIII) can be between about 20,000 Daltons and about 50,000 Daltons.
- the value of the integer p can be between about 14 and about 360.
- a copolymer having formula (XIX) can be synthesized and used in practice of the invention.
- the copolymer (XIX) can be synthesized in same way as the copolymer (XVIII) of Example 16, except that a reagent A 2 (amidediol) shown in Table 1 can be used instead of a reagent A 1 (diol-diamine), where R 2 is methylmethylene CH(CH 3 ), and Y is (CH 2 ) 4 .
- a 2 can be synthesized by condensation of lactic acid with putrescine.
- C 2 can be a PEG-dicarboxylic acid shown in Table 5 derived from poly(ethylene glycol) having molecular weight of about 1,000 Daltons, which is symbolized by the abbreviation PEG 1000 .
- a total molecular weight of the copolymer (XIX) can be between about 20,000 Daltons and about 50,000 Daltons.
- the value of the integer p can be between about 15 and about 390.
- Co-poly- ⁇ [N,N′-adipoyl-bis-(L-alanine)-1,4-butylene diester] 37 -[N,N′-adipoyl-bis-(L-alanine)-PEG300 diester] 67 ⁇ having formula (XX) can be synthesized and used in practice of the invention.
- This copolymer belongs to category (A), type A 1 -B 1 —C 1 , described above.
- the mixture can be stirred until full dissolution and then the temperature can be raised to about 80° C. After stirring for about 24 hours, the viscous mixture can be cooled to room temperature, diluted with about 100 ml ethanol, and precipitated into an excess of water. The separated polymer can be thoroughly washed with water, spread thinly onto a TEFLON pan, and dried at room temperature under vacuum (about 70 mm Hg) for about 24 hours.
- amide bonds are formed in the presence of existing ester bonds, mild conditions need to be used, and this will be understood by those having ordinary skill in the art.
- polymerization techniques using good leaving groups such as para-nitrophenol or carboxyl groups activated by carbodiimides can be used.
- the range of stoichiometries can be determined by the desired mass content of PEG.
- the final polymer can contain between about 5 mass % and about 50 mass % of PEG.
- this corresponds to molar ratios of the two blocks of (alanine/butanediol-adipic acid) (A 1 -C 1 blocks) and (alanine/PEG-adipic acid) (B 1 —C 1 blocks) between about 94:6 and about 12:88.
- Co-poly- ⁇ [N,N′-sebacyl-1,4-butylene diamide] 86 -[N,N′-sebacyl-(ED-600) diamide] 14 ⁇ having formula (XXI) can be synthesized and used in practice of the invention.
- This copolymer belongs to category (B), type (A 4 -B 4 —C 1 ), described above.
- ED-600 is an abbreviation symbolizing JEFFAMINE ED-600 polymer described above (see Example 4).
- the mass contents of PEG in the final copolymer (XXI) can be between about 5 mass % and about 50 mass %. For copolymer (XXI), this corresponds to molar ratios of the two blocks of diamine-sebacic acid (A 4 -C 1 blocks) and ED-600-sebacic acid (B 4 —C 1 blocks) of between about 97:3 and about 57:43.
- Co-poly- ⁇ [N,N′-succinyl-bis-(L-leucine)-1,3-propylene diester] 82 -[succinyl-PEG 600 diester] 18 ⁇ having formula (XXII) can be synthesized and used in practice of the invention.
- This copolymer belongs to category (C), type (A 1 -B 3 —C 1 ), described above.
- reaction mixture can be filtered through filter paper to remove the urea byproduct, and the solution can be placed into a reaction flask.
- the following compounds can then be added to the reaction mixture with continued stirring:
- the mixture can be stirred at room temperature for about 2 hours and then the temperature can be increased to about 60° C. and stirred for about two more hours.
- the polymer can precipitated by adding the reaction solution dropwise to about 2 liters of ethyl acetate with stirring.
- the precipitated polymer can be placed as a thin layer into a TEFLON pan and dried at room temperature under vacuum (about 70 mm Hg) for about 24 hours.
- both amide and ester bonds are present in the copolymer. Accordingly, mild conditions need to be used, as understood by those having ordinary skill in the art. For example, carboxylate groups activated by carbodiimides can be used or good leaving groups such as para-nitro-phenol can be used.
- the mass contents of PEG in the final copolymer (XXII) can be between about 5 mass % and about 50 mass %.
- copolymer (XXII) corresponds to molar ratios of the two blocks of leucine/propanediol-succinic acid (A 1 -C 1 blocks) and PEG-diol-succinic acid (B 3 —C 1 blocks) between about 94:6 and about 12:88.
- Co-poly- ⁇ [terephthalyl-bis-(D,L-lactate)-1,4-butylene diamide] 81 -[terphthalyl-bis-(glycolate)-ED600 diamide] 19 ⁇ having formula (XXIII) can be synthesized and used in practice of the invention.
- This copolymer belongs to category (D), type (A 2 -B 2 —C 1 ), described above.
- the flask can be sealed and heated to about 180° C. for about 2 hours. After about 2 hours, the pressure can be reduced to about 0.1 Torr, and the solution can be maintained at about 180° C. for about two more hours.
- a first composition can be prepared, the composition including:
- the first composition can be applied onto the surface of bare 12 mm VISION stent (available from Guidant Corporation). Coating can be sprayed and dried to form a drug-polymer layer.
- a spray coater can be used having a 0.014 round nozzle maintained at ambient temperature with a feed pressure of about 2.5 psi (0.17 atm) and an atomization pressure of about 15 psi (1.02 atm). Coating can be applied at about 20 ⁇ g per pass. Between the passes the stent can be dried for about 10 seconds in a flowing air stream at about 50° C. About 270 ⁇ g of wet coating can be applied. The stent can be baked at about 50° C. for about one hour, yielding a drug-polymer layer containing about 250 ⁇ g of dry coating.
- a second composition can be prepared by mixing the following components:
- the second composition can be applied onto the dry drug-polymer layer to form the topcoat layer.
- the same spraying technique and equipment can be used for the applying the topcoat layer as described for the drug-polymer layer.
- About 120 ⁇ g of wet coating can be applied, followed by drying, e.g., baking at about 50° C. for about one hour, yielding about 100 ⁇ g of a biocompatible topcoat layer.
- a first composition can be prepared by mixing the following components:
- the first composition can be applied onto the surface of bare 12 mm VISION stent using equipment and coating technique described in Example 22. About 120 ⁇ g of wet coating can be applied.
- the stents can be baked at about 50° C. for about one hour, yielding about 100 ⁇ g of a dry primer layer.
- the copolymer forming the primer layer includes 4-amino-TEMPO (4-amino-2,2′,6,6′-tetramethylpiperidine-1-oxy) moiety attached to lysine via an amide linkage.
- a second composition can be prepared by mixing the following components:
- the second composition can be applied onto the dry primer layer, to form the pure drug layer.
- the same spraying technique and equipment can be used for the applying the drug layer as described above.
- Coating can be applied at about 20 ⁇ g per pass. Between the passes the stent can be dried for about 10 seconds in a flowing air stream at about 50° C. About 110 ⁇ g of neat drug coating can be applied. The stent can be baked at about 50° C. for about one hour, yielding a pure dry drug-layer containing about 100 ⁇ g of dry coating.
- a third composition can be prepared by mixing the following components:
- the third composition can be applied onto the dry pure drug layer to form the topcoat layer.
- the same spraying technique and equipment can be used for the applying the topcoat layer as described above.
- About 440 ⁇ g of wet coating can be applied, followed by drying, e.g., baking at about 50° C. for about one hour, yielding about 400 ⁇ g of a biocompatible topcoat layer, which can also control the release of the drug.
Abstract
Coatings for an implantable medical device and a method of fabricating thereof are disclosed, and the coatings comprise biologically absorbable poly(ester amides).
Description
- This application is a continuation application of U.S. application Ser. No. 10/805,036 filed on Mar. 16, 2004, the teaching of which is incorporated by reference in its entirety herein.
- 1. Field of the Invention
- This invention is directed to coatings for drug delivery devices, such as drug eluting vascular stents, and methods for producing the same.
- 2. Description of the State of the Art
- Percutaneous transluminal coronary angioplasty (PTCA) is a procedure for treating heart disease. A catheter assembly having a balloon portion is introduced percutaneously into the cardiovascular system of a patient via the brachial or femoral artery. The catheter assembly is advanced through the coronary vasculature until the balloon portion is positioned across the occlusive lesion. Once in position across the lesion, the balloon is inflated to a predetermined size to radially compress against the atherosclerotic plaque of the lesion to remodel the lumen wall. The balloon is then deflated to a smaller profile to allow the catheter to be withdrawn from the patient's vasculature.
- A problem associated with the above procedure includes formation of intimal flaps or torn arterial linings which can collapse and occlude the conduit after the balloon is deflated. Moreover, thrombosis and restenosis of the artery may develop over several months after the procedure, which may require another angioplasty procedure or a surgical by-pass operation. To reduce the partial or total occlusion of the artery by the collapse of arterial lining and to reduce the chance of the development of thrombosis and restenosis, a stent is implanted in the lumen to maintain the vascular patency.
- Stents are used not only as a mechanical intervention but also as a vehicle for providing biological therapy. As a mechanical intervention, stents act as scaffoldings, functioning to physically hold open and, if desired, to expand the wall of the passageway. Typically, stents are capable of being compressed, so that they can be inserted through small vessels via catheters, and then expanded to a larger diameter once they are at the desired location. Examples in patent literature disclosing stents which have been applied in PTCA procedures include stents illustrated in U.S. Pat. No. 4,733,665 issued to Palmaz, U.S. Pat. No. 4,800,882 issued to Gianturco, and U.S. Pat. No. 4,886,062 issued to Wiktor.
- Biological therapy can be achieved by medicating the stents. Medicated stents provide for the local administration of a therapeutic substance at the diseased site. In order to provide an efficacious concentration to the treated site, systemic administration of such medication often produces adverse or toxic side effects for the patient. Local delivery is a preferred method of treatment in that smaller total levels of medication are administered in comparison to systemic dosages, but are concentrated at a specific site. Local delivery thus produces fewer side effects and achieves more favorable results. One proposed method for medicating stents involves the use of a polymeric carrier coated onto the surface of a stent. A solution which includes a solvent, a polymer dissolved in the solvent, and a therapeutic substance dispersed in the blend is applied to the stent. The solvent is allowed to evaporate, leaving on the stent surface a coating of the polymer and the therapeutic substance impregnated in the polymer.
- One polymer that can be used for making stent coatings for local drug delivery can be selected from a group of poly(ester amides) described in U.S. Pat. No. 6,503,538 to Chu et al. However, some mechanical properties, such as hardness of the poly(ester amides) taught by Chu et al. may be insufficiently good for stent applications. Accordingly, there is a need to have poly(ester amides) with better properties to allow the poly(ester amides) to be used to make stent coatings for local drug delivery.
- According to one aspect of the present invention, a medical article is provided, the article comprises an implantable substrate having a coating, the coating includes a polymeric product of a reaction between a first reagent, a second reagent, and a third reagent, wherein: (a) the first reagent can be one of the compounds having formulae (1), (2), (3), and (4);
- (b) the second reagent can be one of the compounds having formulae (5), (6), (7), and (8);
- and, (c) the third reagent can be a dicarboxylic acid having the formula (9):
- In formulae (1)-(9), R1 can be hydrogen, methyl, iso-propyl, sec-butyl; iso-butyl, or benzyl group; R2 can be methylene, methylmethylene, n-propylene, iso-propylene, ethylmethylene, n-butylene, iso-butylene, sec-butylene, or n-amylene group; R3 can be a straight chained or branched aliphatic alkylene group CnH2n, wherein n is an integer between 2 and 12; R4 can be a moiety derived from a compound selected from a group consisting of poly(ethylene glycol), poly(propylene glycol), random poly(ethylene glycol-co-propylene glycol), poly(ethylene glycol)-block-poly(propylene glycol), hyaluronic acid, poly(2-hydroxyethyl methacrylate), poly(3-hydroxypropylmethacrylamide), poly(styrene sulfonate), poly(vinyl pyrrolidone), and cellulosics; X can be a straight chained or branched aliphatic alkylene group CnH2n, wherein n is an integer between 2 and 12; and Y can be a straight chained or branched aliphatic alkylene group CnH2n, wherein n is 1, 2, or 5.
- According to another aspect of the present invention, a medical article is provided. The article comprises an implantable substrate having a coating, and the coating includes a copolymer having a general formula (10) or (11):
-
-[M-P]m-[M-Q]n- (10) -
-[M-P]- (11) - wherein, M can be a moiety represented by the structure having the formula (12);
- P can be one of the moieties having the formulae (13), (14), (15), and (16);
- Q can be one of the moieties having the formulae (17), (18), and (19);
- and M1 can be a moiety represented by the formula (20);
- In formulae (10)-(20), R1 can be hydrogen, methyl, iso-propyl, sec-butyl; iso-butyl, or benzyl group; R2 can be methylene, methylmethylene, n-propylene, iso-propylene, ethylmethylene, n-butylene, iso-butylene, sec-butylene, or n-amylene group; R3 can be a straight chained or branched aliphatic alkylene group CnH2n, wherein n is an integer between 2 and 12; X can be a straight chained or branched aliphatic alkylene group CnH2n, wherein n is an integer between 2 and 12; Y can be a straight chained or branched aliphatic alkylene group CnH2n, wherein n is 1, 2, or 5; Z can be a moiety derived from a compound selected from a group consisting of poly(ethylene glycol), poly(propylene glycol), random poly(ethylene glycol-co-propylene glycol), poly(ethylene glycol)-block-poly(propylene glycol), hyaluronic acid, poly(2-hydroxyethyl methacrylate), poly(3-hydroxypropylmethacrylamide), poly(styrene sulfonate), poly(vinyl pyrrolidone), and cellulosics; and m, n, and p can be integers where the value of m is between 5 and 1,800, the value of n is between 1 and 800 and the value of p is between 4 and 1,500.
- According to yet another aspect of the current invention, a method for fabricating a medical article is provided, the method includes synthesizing a copolymer and forming a coating based on the copolymer on at least a portion of an implantable substrate, the synthesizing of the copolymer including reacting a first reagent with a second reagent and with a third reagent, wherein: (a) the first reagent can be one of the compounds having formulae (1), (2), (3), and (4); (b) the second reagent can be one of the compounds having formulae (5), (6), (7), and (8); and (c) the third reagent is a dicarboxylic acid having the formula (9), where the formulae (1)-(9) are provided above.
- According to yet another aspect of the current invention, a method for fabricating a medical article is provided, the method including synthesizing a copolymer and forming a coating based on the copolymer on at least a portion of an implantable substrate, wherein the copolymer has a general formula (10) or (11), where the formulae (10) and (11) are provided above.
- The following definitions apply:
- The term “biologically absorbable” coatings and/or polymers is defined as coatings and/or polymers that are capable of being completely degraded and/or eroded when exposed to bodily fluids such as blood and are gradually resorbed, absorbed and/or eliminated by the body. The processes of breaking down and eventual absorption and elimination of the coating and/or polymer can be caused, for example, by hydrolysis, metabolic processes, bulk or surface erosion, and the like.
- Whenever the reference is made to “biologically absorbable” stent coatings and/or polymers forming such stent coatings, it is understood that after the process of degradation, erosion, absorption, and/or resorption has been completed, no coating, in excess of possibly insignificant trace amount, will remain on the stent. In other words, stent coatings and/or polymers forming such stent coatings are considered “biologically absorbable” if the coatings and/or polymers are substantially broken down by the in vivo environment, or by the in vitro environment, such as one having physical, chemical, and/or biological characteristics substantially similar to those of the in vivo environment. An amount of time needed to break down the coatings and/or polymers can be between about 1 day and several years, or between about 1 day and about 24 months; alternatively, between about 2 months and about 18 months; alternatively, between about 3 month and about 12 months.
- For purposes of the present invention, “substantially broken down” means that a substantial reduction of the molecular weight of a polymer occurs as a result of the exposure of the polymer to the in vivo environment or to a simulated in vivo environment. The simulated in vivo environment can be the in vitro environment having physical, chemical, and/or biological characteristics that are identical or substantially similar to those of the in vivo environment. Standard analytical techniques normally used by those having ordinary skill in the art can be used to monitor the change of the molecular weight of the polymer. One analytical technique that can be used includes immersing the polymer in a simulated in vivo environment and measuring the loss of the molecular weight of the polymer over time. A number of methods can be used for measuring the molecular weight, for example, gel permeation chromatography (GPC). In some embodiments, if the polymer has lost more than about 10% of its original molecular weight over a 3-month period, then it can be classified as biodegradable.
- The term “poly(ester amide)” or “PEA” is defined as a polymer having both at least one ester bond (I) and at least one amide bond (II):
- A coating for an implantable medical device, such as a stent, according to embodiments of the present invention, can be a multi-layer structure that can include the following three layers:
- (a) a drug-polymer layer (also referred to as “reservoir” or “reservoir layer”), comprising a polymer and a drug, or alternatively a polymer free drug layer;
- (b) an optional primer layer; and/or
- (c) an optional topcoat layer.
- Each layer of the stent coating can be formed on the stent by dissolving a polymer or a blend of polymers in a solvent, or a mixture of solvents, and applying the resulting polymer solution on the stent by spraying or immersing the stent in the solution. After the solution has been applied onto the stent, the coating is dried by allowing the solvent to evaporate. The process of drying can be accelerated if the drying is conducted at an elevated temperature.
- To incorporate a drug into the reservoir layer, the drug can be combined with the polymer solution that is applied onto the stent as described above. Alternatively, to fabricate a polymer-free drug layer, the drug can be dissolved in a suitable solvent or mixture of solvents, and the resulting drug solution can be applied on the stent by spraying or immersing the stent in the drug solution.
- Instead of introducing the drug as a solution, the drug can be introduced as a colloid system, such as a suspension in an appropriate solvent phase. To make the suspension, the drug can be dispersed in the solvent phase using conventional techniques used in colloid chemistry. Depending on a variety of factors, e.g., the nature of the drug, those having ordinary skill in the art can select the solvent to form the solvent phase of the suspension, as well as the quantity of the drug to be dispersed in the solvent phase. The suspension can be mixed with a polymer solution and the mixture can be applied on the stent as described above. Alternatively, the drug suspension can be applied on the stent without being mixed with the polymer solution.
- The drug-polymer layer can be applied directly onto at least a part of the stent surface to serve as a reservoir for at least one active agent or a drug which is incorporated into the reservoir layer. The optional primer layer can be applied between the stent and the reservoir to improve the adhesion of the drug-polymer layer to the stent. The optional topcoat layer can be applied over at least a portion of the reservoir layer and to serve as a rate limiting membrane which helps to control the rate of release of the drug. The topcoat layer can be essentially free from any active agents or drugs.
- In one embodiment, any or all of the layers of the stent coating, can be made of a polymer that is both biologically beneficial and biologically degradable, erodable, absorbable, and/or resorbable. In another embodiment, just the outermost layer of the coating can be limited to such a polymer.
- To illustrate in more detail, in the stent coating having all three layers described above (i.e., the primer, the reservoir layer, and the topcoat layer), the outermost layer is the topcoat layer, which is made of a biologically absorbable block copolymer. In this case, optionally, the remaining layers (i.e., the primer and the reservoir layer) can be also fabricated of a biologically absorbable block copolymer; the block copolymer can be the same or different in each layer. If the topcoat layer is not used, the stent coating can have only two layers: the optional primer and the reservoir. The reservoir in this case is the outermost layer of the stent coating and is made of a biologically absorbable block copolymer. Optionally, the primer can be also fabricated of a biologically absorbable block copolymer, which can be the same or different in the reservoir and in the primer. In one embodiment, the biologically absorbable copolymers that can be used for making any of the stent coating layers include poly(ester amides) (PEA). Optionally, in some other embodiments, condensation copolymers, such as poly(esters) having no amide bonds, can be used instead of PEAs.
- The synthetic techniques that can be used for obtaining both the PEAs and the poly(esters) are described below in the application. Generally, the PEAs are products of reaction between at least one reagent from group A, at least one reagent from group B and a reagent C1 from group C. The poly(esters) are products of reaction between at least one reagent from group A and a reagent C2 from group C. The precursor-reagents from groups A, B, and C that can be used are characterized as follows.
- A. Group A Reagents.
- The group A precursor-reagents (hereinafter, “reagents”) that can be used for synthesizing the biologically absorbable copolymers according to embodiments of the present invention are summarized in Table 1. The definition used to describe a chemical family to which each of the group A reagents belongs is also provided in Table 1.
- In the general formulae of compounds A1, A2, A3, and A4 presented in Table 1, the substitutents R1, R2, X, and Y can be as follows:
- R1— (a) hydrogen;
- (b) methyl (—CH3);
- (c) iso-propyl (-i-C3H7);
- (d) sec-butyl (-sec-C4H9);
- (e) iso-butyl (-i-C4H9); or
- (f) benzyl (—C6H5);
- R2— (a) methylene (—CH2—);
- (b) ethylene (—CH2CH2—);
- (c) methylmethylene [—CH(CH3)—];
- (d) straight chained or branched propylene, such as:
-
- (d1) n-propylene (—CH2CH2CH2—);
- (d2) iso-propylene [—CH2CH(CH3)—]; or
- (d3) ethylmethylene [—CH(CH2CH3)—];
- (e) straight chained or branched butylene, such as:
-
- (e1) n-butylene (—CH2CH2CH2CH2—),
- (e2) iso-butylene [—CH2CH(CH3)CH2—], or
- (e3) sec-butylene [—CH(CH2CH3)CH2—];
- (f) straight chained or branched pentylene, such as:
-
- (f1) n-pentylene (—CHCH2CH2CH2CH2—),
- (f2) iso-pentylene [—C(CH3)2CH2CH2—],
- (f3) neopentylene {—CH[C(CH3)3]—},
- (f4) 2-methyl-1-butylene [—C(CH3)(CH2CH3)CH2—],
- (f5) sec-iso-pentylene [—C(CH3)2CH(CH3)—], or
- (f6) methylpropylmethylene [—C(CH3)(CH2CH2CH3)—]; or
- (g) groups that are present in some amino acids, such as:
-
- (g1) methyleneamide (present in asparagine) [—CH2(CONH2)—];
- (g2) ethyleneamide (present in glutamine) [—CH2CH2(CONH2)—];
- (g3) methylmercaptomethylmethylene (present in methionine) [—CH2(CH2SCH3)—]; or
- (g4) n-propyleneamino group (—CH2CH2CH2NH—) which is derived from 2-pyrrolidine group present (present in proline);
- X—straight chained or branched aliphatic alkylene group C1H2n, wherein n is an integer between 2 and 16, e.g., methylene, ethylene, propylene, butylene, amylene (pentylene), hexylene, heptylene, octylene, nonylene, decylene, undecylene, or dodecylene group; and
- Y—straight chained or branched aliphatic alkylene group C2H4 (ethylene), C3H6 (propylene), C4H8 (butylene), or C5H10 (pentylene also known as amylene).
- The reagent A1 is a diol-diamine that can be synthesized by condensation of two molar equivalents of an amino acid and one molar equivalent of a diol. The synthesis can be carried under the conditions favoring esterification of the amino acid via the amino acid's carboxyl group. The reaction can be conducted under dehydrating conditions which include anhydrous environment and an elevated temperature, for example, about 50° C., and can be catalyzed by a strong acid or base, e.g., p-toluenesulfonic acid.
- The diol that can be used to make the reagent A1 has the formula HO—X—OH, where X is as defined above. Representative examples of diols that can be used include ethylene glycol, 1,3-propanediol, 1,4-butane diol, 1,5-pentanediol, 1,6-hexanediol, 1,7-heptanediol, 1,8-octanediol, 1,9-nonanediol, 1,10-decanediol, 1,11-undecanediol, and 1,12-dodecanediol. The amino acid that can be used to make the reagent A1 has the formula H2N—CHR1—COOH, where R1 is as defined above. Some amino acids that can be used are summarized in Table 2.
-
TABLE 2 Amino Acids That Can Be Used for Making the Reagent A1 Amino Acid (H2N—CHR1—COOH) No. R1 Formula Name 1 —H H2N—CH2—COOH glycine 2 —CH3 alanine 3 —i-C3H7 valine 4 —sec-C4H9 isoleucine 5 —i-C4H9 leucine 6 C6H5CH2— phenyl alanine 7 —(CH2)2—S—CH3 methionine (α-amino-γ- methylmercaptobutyric acid) 8 —CH2—C(O)—NH2 asparagine (α-amine- succinamic acid) 9 —(CH2—C(O)—NH2 glutamine (2-amino- glutaramic acid) - In addition to amino acids listed in Table 2, alternatively other amino acids can be used. One example of such alternative amino acids is proline (2-pyrrolidine carboxylic acid). Other alternative amino acids that can be used include some amino acids having free hydroxyl groups or second carboxyl groups if the free hydroxyl groups or the second carboxyl groups are protected first. The protection is needed so as to avoid interference when reagent A1 is subsequently reacted with reagents of groups B and C, as discussed above. Examples of the amino acids that can be used after the free hydroxyl or second carboxyl groups are protected include tyrosine, serine, or glutamic acid.
- The reagent A2 is an amidediol that can be synthesized by condensation of two molar equivalents of a hydroxy acid and one molar equivalent of a diamine. The synthesis can be carried under the conditions favoring formation of an amide bond. The reaction can be conducted under dehydrating conditions, which include anhydrous environment and can be catalyzed by a strong base. Simple heating of the neat starting materials with the simultaneous removal of generated water by distillation can also be used.
- The diamine that can be used to make the reagent A2 has the formula H2N—Y—NH2, where Y is as defined above. Accordingly, examples of diamines that can be used include 1,4-butanediamine (putrescine) (Y═CH2CH2CH2CH2). Alternatively, other diamines, such as 1,2-ethanediamine (Y═CH2CH2) or 1,5-pentanediamine (cadavarene) (Y═CH2CH2CH2CH2CH2) can be used. The hydroxy acid that can be used to make the reagent A2 has the formula HO—R2—COOH, where R2 is as defined above. Some hydroxy acids that can be used are summarized in Table 3.
-
TABLE 3 Hydroxy Acids That Can Be Used For Making The Reagent A2 Hydroxy Acid (HO—R2—COOH) No. R2 Formula Name 1 —CH2— HO—CH2—COOH glycolic (hydroxyacetic) acid 2 —CH2—CH2— HO—CH2—CH2—COOH β-hydroxypropionic acid 3 lactic (α- hydroxypropionic) acid 4 β-hydroxybutyric acid 5 α-hydroxyvaleric acid 6 β-hydroxyvaleric acid 7 —(CH2)5— HO—(CH2)5—COOH ε-hydroxycaproic acid 8 α-hydroxycaproic acid 8 β-hydroxycaproic acid 9 δ-hydroxycaproic acid - The reagent A3 is a common simple diol having the formula HO—X—OH, where X is as defined above; and the reagent A4 is a common simple diamine having the formula H2N—Y—NH2, where Y is as defined above.
- B. Group B Reagents.
- The group B reagents that can be used for synthesizing the biologically absorbable copolymers according to embodiments of the present invention are summarized in Table 4. Exemplary definitions used to describe a chemical family to which each of the group B reagents belongs is also provided in Table 4.
- In general formulae of compounds B1, B2, B3, and B4 presented in Table 4, the substitutents R1 and R2 are as defined above. One example of the R4 moiety that can be used is a moiety derived from poly(ethylene glycol) (PEG). Alternatively, other biologically beneficial moieties can be used as R4, for example, moieties derived from poly(propylene glycol) (PPG), random or block copolymers of PEG and PPG, hyaluronic acid, poly(2-hydroxyethylmethacrylate), poly(3-hydroxypropylmethacrylamide), or cellulosics.
- The reagent B1 can be a PEG-diester-diamine moiety (i.e., when R4=PEG) that can be synthesized by condensation of two molar equivalents of an amino acid and one molar equivalent of PEG. The synthesis can be carried under the conditions favoring esterification of the amino acid via the carboxyl group. The reaction can be conducted under dehydrating conditions which include anhydrous environment and an elevated temperature, for example, about 50° C., and can be catalyzed by a strong acid or base, e.g., p-toluenesulfonic acid. To make the reagent B1, PEG having molecular weight between about 100 and 4,000 Daltons, for example, about 300 Daltons, can be used. Any amino acid listed in Table 2 can be used. Alternatively, other amino acids can be used, for example, tyrosine, serine, or glutamic acid, if free hydroxyl groups of tyrosine and serine or the second carboxyl group of glutamic acid are protected so as not to interfere when reagent B1 is subsequently reacted with reagents of groups A and C, as discussed above.
- The reagent B2 can be a PEG-amidediol that can be synthesized by condensation of two molar equivalents of a hydroxy acid and one molar equivalent of a PEG-diamine. The synthesis can be carried under the conditions favoring formation of an amide bond. The reaction can be conducted under dehydrating conditions which include anhydrous environment, and can be catalyzed by a strong base, or prepared from neat reagents by heating at high temperature with the simultaneous removal of generated water, e.g., the removal of water by distillation. Any hydroxy acid listed in Table 3 can be used. PEG terminated with amino groups on both ends (PEG-diamine reagent B4) can be obtained from Huntsman Chemical Co. of Houston, Tex. under the trade name JEFFAMINE.
- C. Group C Reagents.
- The group C reagents that can be used for synthesizing the biologically absorbable copolymers according to embodiments of the present invention are summarized in Table 5. The definition used to describe a chemical family to which each of the group C reagents belongs is also provided in Table 5.
- In general formula of compound C1 presented in Table 5, the substituent R3 is simply a covalent bond, or a straight chained or branched aliphatic alkylene group C1H2n, wherein n is an integer having a value between 0 and 12, e.g. a single bond (n=0), methylene, ethylene, propylene, butylene, amylene (pentylene), hexylene, heptylene, octylene, nonylene, decylene, undecylene, or dodecylene group, or an aromatic group, e.g., phenyl or para-phenylene. Some examples of dicarboxylic acids that can be used as the reagent C1 are summarized in Table 6.
-
TABLE 6 Dicarboxylic Acids That Can Be Used As The Reagent C1 Dicarboxylic Acid (HOOC—R3—COOH) No. R3 Formula Name 1 —(CH2)2— HOOC—(CH2)2—COOH succinic (butanedioic) acid 2 —(CH2)4— HOOC—(CH2)4—COOH adipic (hexanedioic) acid 3 —(CH2)8— HOOC—(CH2)8—COOH sebacic (decanedioic) acid 4 (p)-C6H4— HOOC-(p)C6H4—COOH terephthalic (1,4- benzene dicarboxylic) acid - In addition to the dicarboxylic acids listed in Table 6, examples of other dicarboxylic acids that can be also used include oxalic acid, malonic acid, glutaric acid, pimelic acid, suberic acid, or azelaic acid. As mentioned above, to synthesize the PEAs, at least one reagent of group A can be reacted with at least one reagent of group B and reagent C1. To make the poly(esters), at least one reagent of group A can be reacted with reagent C2.
- One of several routes can be utilized to synthesize the polymers of this invention. Those having ordinary skill in the art can appreciate that the reagents of groups A, B, and C may themselves contain hydrolysable bonds, i.e. ester or amide bonds. These reagents can be then polymerized, the polymerization creating additional bonds that may be both ester and amide bonds, only amide bonds, or only ester bonds. Given that the reagents can be obtained separately, the types of polymers formed during the polymerization can belong to one of the following four categories (A), (B), (C), or (D):
- (A) Polymers in which amide bonds are formed between reagents which themselves contain ester bonds. Using the reagent codes defined earlier, these polymers can be described as products of reaction between:
-
- (1) A1, B1 and C1 (A1-B1—C1);
- (2) A1, B4 and C1 (A1-B4—C1);
- (3) A4, B1 and C1 (A4-B1—C1); and
- (4) A1 and C2 (A1-C2).
- (B) Polymers in which amide bonds are formed between reagents which themselves contain neither ester nor amide bonds. Using the reagent codes defined earlier, these polymers can be described as products of reaction between:
-
- (1) A4, B4 and C1 (A4-B4—C1); and
- (2) A4 and C2 (A4-C2).
- (C) Polymers in which both ester and amide bonds are formed between the reagents. The subunits themselves may contain ester and amide bonds, only ester bonds, only amide bonds, or neither ester nor amide bonds. Using the reagent codes defined earlier, these polymers can be described as products of reaction between:
-
- (1) A1, B2 and C1 (A1-B2—C1);
- (2) A1, B3 and C1 (A1-B3—C1);
- (3) A2, B1 and C1 (A2-B1—C1);
- (4) A2, B4 and C1 (A2-B4—C1);
- (5) A3, B1 and C1 (A3-B1—C1);
- (6) A3, B4 and C1 (A3-B4—C1);
- (7) A4, B2 and C1 (A4-B2—C1); and
- (8) A4, B3 and C1 (A4-B3—C1).
- (D) Polymers in which ester bonds are formed between reagents which themselves may contain amide bonds, or neither amide nor ester bonds. Using the reagent codes defined earlier, these polymers can be described as products of reaction between:
-
- (1) A2, B2 and C1 (A2-B2—C1);
- (2) A2, B3 and C1 (A2-B3—C1);
- (3) A2 and C2 (A2-C2);
- (4) A3, B2 and C1 (A3-B2—C1);
- (5) A3, B3 and C1 (A3-B3—C1); and
- (6) A3 and C2 (A3-C2).
- Due to the types of bonds being formed, and the types of bonds present, those having ordinary skill in the art will understand that the polymerization scheme need be adjusted for each category in order to form the desired polymer while not hydrolyzing or degrading the existing bonds in the reagents, or creating uncontrolled, mixed species. Some examples of the synthesis of particular polymers are provided below in the “Examples” section of the present application.
- As a result of the synthesis, biologically absorbable PEAs having a general formula (A) or poly(esters) having a general formula (B) can be obtained:
-
-[M-P]m-[M-Q]n- (A) -
-[M1P]p- (B) - wherein:
- M is a moiety represented by the structure
- P is a moiety including
- Q is a moiety selected from a group consisting of
- M1 is a moiety represented by the structure
- R1, R2, R3, X and Y are substitutents and moieties as defined above;
- Z is a moiety that can be derived from a compound selected from a group consisting of poly(ethylene glycol)(PEG), poly(propylene glycol) (PPG), random or block copolymers of PEG and PPG, hyaluronic acid, poly(2-hydroxyethylmethacrylate), poly(3-hydroxypropyl methacrylamide), poly(styrene sulfonate), poly(vinyl pyrrolidone), and cellulosics; and
- m, n, and p are integers where the value of m can be between 5 and 1,800, the value of n can be between 1 and 800 and the value of p can be between 4 and 1,500.
- Any layer of the stent coating can contain any amount of the biologically absorbable copolymers described above, or a blend of more than one of such copolymers. If less than 100% of the layer is made of the biologically absorbable copolymers, or blends thereof, described above, alternative polymers can comprise the balance. Examples of the alternative polymers that can be used include polyacrylates, such as poly(butyl methacrylate), poly(ethyl methacrylate), and poly(ethyl methacrylate-co-butyl methacrylate), and fluorinated polymers and/or copolymers, such as poly(vinylidene fluoride) and poly(vinylidene fluoride-co-hexafluoropropene), poly(N-vinyl pyrrolidone), poly(hydroxyvalerate), poly(L-lactic acid), polycaprolactone, poly(lactide-co-glycolide), poly(hydroxybutyrate), poly(hydroxybutyrate-co-valerate), polydioxanone, polyorthoester, polyanhydride, poly(glycolic acid), poly(D,L-lactic acid), poly(glycolic acid-co-trimethylene carbonate), polyphosphoester, polyphosphoester urethane, poly(amino acids), cyanoacrylates, poly(trimethylene carbonate), poly(iminocarbonate), co-poly(ether-esters), polyalkylene oxalates, polyphosphazenes, biomolecules (such as fibrin, fibrinogen, cellulose, starch, collagen and hyaluronic acid), polyurethanes, silicones, polyesters, polyolefins, polyisobutylene and ethylene-alphaolefin copolymers, vinyl halide polymers and copolymers (such as polyvinyl chloride), polyvinyl ethers (such as polyvinyl methyl ether), polyvinylidene chloride, polyacrylonitrile, polyvinyl ketones, polyvinyl aromatics (such as polystyrene), polyvinyl esters (such as polyvinyl acetate), copolymers of vinyl monomers with each other and olefins, e.g., poly(ethylene-co-vinyl alcohol) (EVAL), ethylene-methyl methacrylate copolymers, acrylonitrile-styrene copolymers, ABS resins, and ethylene-vinyl acetate copolymers; polyamides (such as Nylon 66 and polycaprolactam), alkyd resins, polycarbonates, polyoxymethylenes, polyimides, polyethers, epoxy resins, polyurethanes, rayon, rayon-triacetate, cellulose, cellulose acetate, cellulose butyrate, cellulose acetate butyrate, cellophane, cellulose nitrate, cellulose propionate, cellulose ethers, and carboxymethyl cellulose.
- Representative examples of some solvents suitable for making the stent coatings include N,N-dimethylacetamide (DMAC), N,N-dimethylformamide (DMF), tethrahydrofurane (THF), cyclohexanone, xylene, toluene, acetone, i-propanol, methyl ethyl ketone, propylene glycol monomethyl ether, methyl butyl ketone, ethyl acetate, n-butyl acetate, and dioxane. Some solvent mixtures can be used as well. Representative examples of the mixtures include:
-
- (1) DMAC and methanol (e.g., a 50:50 by mass mixture);
- (2) water, i-propanol, and DMAC (e.g., a 10:3:87 by mass mixture);
- (3) i-propanol, and DMAC (e.g., 80:20, 50:50, or 20:80 by mass mixtures);
- (4) acetone and cyclohexanone (e.g., 80:20, 50:50, or 20:80 by mass mixtures);
- (5) acetone and xylene (e.g. a 50:50 by mass mixture);
- (6) acetone, FLUX REMOVER AMS, and xylene (e.g., a 10:50:40 by mass mixture); and
- (7) 1,1,2-trichloroethane and chloroform (e.g., a 80:20 by mass mixture).
- FLUX REMOVER AMS is trade name of a solvent manufactured by Tech Spray, Inc. of Amarillo, Tex. comprising about 93.7% of a mixture of 3,3-dichloro-1,1,1,2,2-pentafluoropropane and 1,3-dichloro-1,1,2,2,3-pentafluoropropane, and the balance of methanol, with trace amounts of nitromethane. Those having ordinary skill in the art will select the solvent or a mixture of solvents suitable for a particular polymer being dissolved.
- The therapeutic substance which can be used in the reservoir layer can include any substance capable of exerting a therapeutic or prophylactic effect for a patient. The therapeutic substance may include small molecule substances, peptides, proteins, oligonucleotides, and the like. The therapeutic substance could be designed, for example, to inhibit the activity of vascular smooth muscle cells. It can be directed at inhibiting abnormal or inappropriate migration and/or proliferation of smooth muscle cells to inhibit restenosis.
- Examples of therapeutic substances that can be used include antiproliferative substances such as actinomycin D, or derivatives and analogs thereof (manufactured by Sigma-Aldrich of Milwaukee, Wis., or COSMEGEN available from Merck). Synonyms of actinomycin D include dactinomycin, actinomycin IV, actinomycin I1, actinomycin X1, and actinomycin C1. The active agent can also fall under the genus of antineoplastic, anti-inflammatory, antiplatelet, anticoagulant, antifibrin, antithrombin, antimitotic, antibiotic, antiallergic and antioxidant substances. Examples of such antineoplastics and/or antimitotics include paclitaxel (e.g. TAXOL® by Bristol-Myers Squibb Co., Stamford, Conn.), docetaxel (e.g. Taxotere®, from Aventis S.A., Frankfurt, Germany) methotrexate, azathioprine, vincristine, vinblastine, fluorouracil, doxorubicin hydrochloride (e.g. Adriamycin® from Pharmacia & Upjohn, Peapack N.J.), and mitomycin (e.g. Mutamycin® from Bristol-Myers Squibb Co., Stamford, Conn.). Examples of such antiplatelets, anticoagulants, antifibrin, and antithrombins include sodium heparin, low molecular weight heparins, heparinoids, hirudin, argatroban, forskolin, vapiprost, prostacyclin and prostacyclin analogues, dextran, D-phe-pro-arg-chloromethylketone (synthetic antithrombin), dipyridamole, glycoprotein IIb/IIIa platelet membrane receptor antagonist antibody, recombinant hirudin, and thrombin inhibitors such as ANGIOMAX (Biogen, Inc., Cambridge, Mass.). Examples of such cytostatic or antiproliferative agents include angiopeptin, angiotensin converting enzyme inhibitors such as captopril (e.g. Capoten® and Capozide® from Bristol-Myers Squibb Co., Stamford, Conn.), cilazapril or lisinopril (e.g. Prinivil® and Prinzide® from Merck & Co., Inc., Whitehouse Station, N.J.); calcium channel blockers (such as nifedipine), colchicine, fibroblast growth factor (FGF) antagonists, fish oil (omega 3-fatty acid), histamine antagonists, lovastatin (an inhibitor of HMG-CoA reductase, a cholesterol lowering drug, brand name Mevacor® from Merck & Co., Inc., Whitehouse Station, N.J.), monoclonal antibodies (such as those specific for Platelet-Derived Growth Factor (PDGF) receptors), nitroprusside, phosphodiesterase inhibitors, prostaglandin inhibitors, suramin, serotonin blockers, steroids, thioprotease inhibitors, triazolopyrimidine (a PDGF antagonist), and nitric oxide. An example of an antiallergic agent is permirolast potassium. Other therapeutic substances or agents which may be appropriate include alpha-interferon, genetically engineered epithelial cells, tacrolimus, dexamethasone, and rapamycin and structural derivatives or functional analogs thereof, such as 40-O-(2-hydroxy)ethyl-rapamycin (known by the trade name of EVEROLIMUS available from Novartis), 40-O-(3-hydroxy)propyl-rapamycin, 40-O-[2-(2-hydroxy)ethoxy]ethyl-rapamycin, and 40-O-tetrazole-rapamycin.
- The coatings and methods of the present invention have been described with reference to a stent, e.g., a balloon expandable or self-expandable stent. The use of the coating is not limited to stents, and the coating can also be used with a variety of other medical devices, such as implantable medical devices. Examples of the implantable medical device that can be used in conjunction with the embodiments of this invention include stent-grafts, grafts (e.g., aortic grafts), catheters, guidewires, artificial heart valves, cerebrospinal fluid shunts, pacemaker electrodes, axius coronary shunts and endocardial leads (e.g., FINELINE and ENDOTAK, available from Guidant Corporation). The underlying structure of the device can be of virtually any design. The device can be made of a metallic material or an alloy such as, but not limited to, cobalt-chromium alloys (e.g., ELGILOY), stainless steel (316L), “MP35N,” “MP20N,” ELASTINITE (Nitinol), tantalum, tantalum-based alloys, nickel-titanium alloy, platinum, platinum-based alloys such as, e.g., platinum-iridium alloy, iridium, gold, magnesium, titanium, titanium-based alloys, zirconium-based alloys, or combinations thereof. Devices made from bioabsorbable or biostable polymers can also be used with the embodiments of the present invention. “MP35N” and “MP20N” are trade names for alloys of cobalt, nickel, chromium and molybdenum available from Standard Press Steel Co. of Jenkintown, Pa. “MP35N” consists of 35% cobalt, 35% nickel, 20% chromium, and 10% molybdenum. “MP20N” consists of 50% cobalt, 20% nickel, 20% chromium, and 10% molybdenum.
- Medical devices can be also made from the materials of the invention. Moreover, the polymers can be used for a variety of medical applications, including particles for drug delivery to embolize blood vessels. The polymers of the present invention can have a variety of medical applications, including the treatment of stenosis, restenosis, and cancer.
- The following examples are provided to further illustrate embodiments of the present invention.
- A copolymer having formula (III) can be synthesized and used in practice of the invention.
- The copolymer (III) is a product of copolymerization of reagents A1, B1, and C1. A1 can be a diol-diamine shown in Table 1 where R1 is i-C4H9 and X is (CH2)6. In other words, A1 can be synthesized by condensation of leucine with 1,6-hexanediol. B1 can be a PEG-diester-diamine shown in Table 4 where R1 is i-C4H9 and PEG300 symbolizes a moiety derived from poly(ethylene glycol) having molecular weight of about 300 Daltons. In other words, B1 can be synthesized by condensation of leucine with poly(ethylene glycol) having molecular weight of about 300 Daltons. C1 can be a dicarboxylic acid shown in Table 5 where R3 is (CH2)8 (sebacic acid, which is also shown in Table 6).
- To synthesize copolymer (III), about 30.8 ml dry triethylamine (about 0.22 mole) in about 55 ml dry solvent N,N′-dimethylacetamide at room temperature can be added to a mixture of:
- (a) about 36.37 g (about 0.053 mole) di-para-toluenesulfonic acid salt of bis-(L-leucine)-1,6-hexylene diester;
- (b) about 39.3 g (about 0.047 mole) di-para-toluenesulphonic acid salt of bis-(L-leucine)-PEG300 diester; and
- (c) about 44.4 g (about 0.1 mole) di-para-nitrophenyl sebacinate.
- The mixture can be stirred until full dissolution and then the temperature can be raised to about 80° C. After stirring for about 24 hours, the viscous mixture can be cooled to room temperature, diluted with about 100 ml ethanol, and precipitated into an excess of water. The separated polymer can be thoroughly washed with water, spread thinly onto a TEFLON pan, and dried at room temperature under vacuum (about 70 mm Hg) for about 24 hours.
- A copolymer having formula (IV) can be synthesized and used in practice of the invention.
- The copolymer (IV) is a product of copolymerization of reagents A1, B1, and C1. A1 can be a diol-diamine shown in Table 1, where R1 is CH3 and X is (CH2)4. In other words, A1 can be synthesized by condensation of alanine with 1,4-butanediol. B1 can be a PEG-diester-diamine shown in Table 4 where R1 is i-C4H9 and PEG300 symbolizes a moiety derived from poly(ethylene glycol) having molecular weight of about 300 Daltons. In other words, B1 can be synthesized by condensation of alanine with poly(ethylene glycol) having molecular weight of about 300 Daltons. C1 can be a dicarboxylic acid shown in Table 5 where R3 is (CH2)2 (succinic acid, which is also shown in Table 6).
- To synthesize copolymer (IV), about 30.8 ml dry triethylamine (about 0.22 mole), in about 55 ml dry solvent N,N′-dimethylacetamide, at room temperature, can be added to a mixture of:
- (a) about 30.43 g (about 0.053 mole) di-para-toluenesulfonic acid salt of bis-(L-alanine)-1,4-butylene diester;
- (b) about 36.86 g (about 0.047 mole) di-para-toluenesulfonic acid salt of bis-(L-alanine)-PEG300 diester; and
- (c) about 36.0 g (about 0.1 mole) di-para-nitrophenyl succinate.
- The mixture can be stirred until full dissolution and then the temperature can be raised to about 80° C. After stirring for about 24 hours, the viscous mixture can be cooled to room temperature, diluted with about 100 ml ethanol, and precipitated into an excess of water. The separated polymer is thoroughly washed with water, spread thinly into a TEFLON pan, and dried at room temperature under vacuum (about 70 mm Hg) for about 24 hours.
- A copolymer having formula (V) can be synthesized and used in practice of the invention.
- The copolymer (V) is a product of copolymerization of reagents A1, B1, and C1. A1 can be a diol-diamine shown in Table 1 where R1 is i-C4H9 and X is (CH2)4. In other words, A1 can be synthesized by condensation of leucine with 1,4-butanediol. B1 can be a PEG-diester-diamine shown in Table 4 where R1 is i-C4H9 and PEG300 symbolizes a moiety derived from poly(ethylene glycol) having molecular weight of about 300 Daltons. In other words, B1 can be synthesized by condensation of leucine with poly(ethylene glycol) having molecular weight of about 300 Daltons. C1 can be a dicarboxylic acid shown in Table 5 where R3 is para-C6H4 (terephthalic acid, which is also shown in Table 6).
- The copolymer (V) can be obtained using the same synthetic technique as described in Example 2 for copolymer (IV), except di-para-nitrophenyl terephthalate can be used to make the copolymer (V), instead of di-para-nitrophenyl succinate. In copolymer (V), the value of n can be between about 64 and about 97 and the value of m can be between about 3 and about 36, where m+n=100.
- A copolymer having formula (VI) can be synthesized and used in practice of the invention.
- The copolymer (VI) is a product of copolymerization of reagents A1, B2, and C1. A1 can be a diol-diamine shown in Table 1 where R1 is i-C4H9 and X is (CH2)6. In other words, A1 can be synthesized by condensation of leucine with 1,6-hexanediol. B2 can be a PEG-amidediol shown in Table 4 where R2 is methylmethylene CH(CH3).
- In other words, B2 can be synthesized by condensation of lactic acid with PEG-diamine shown as reagent B4 in Table 4. PEG-diamine can be based on poly(ethylene glycol) having molecular weight of about 600 Daltons, which is symbolized by the abbreviation PEG600.
- For example, JEFFAMINE ED-600 available from Huntsman Corp. can be used. JEFFAMINE ED-600 is a trade name of O,O′-bis-[(2-aminopropyl) poly(propylene glycol)-block-poly(ethylene glycol)-block-poly(propylene glycol)], which is a polyether diamine with a polyalkylene oxide backbone. The molecular weight of JEFFAMINE ED-600 is about 600 Daltons.
- C1 can be a dicarboxylic acid shown in Table 5 where R3 is (CH2)8 (sebacic acid, which is also shown in Table 6). In copolymer (VI), the value of n can be between about 60 and about 93 and the value of m can be between about 7 and about 40, where m+n=100.
- A copolymer having formula (VII) can be synthesized and used in practice of the invention.
- The copolymer (VII) can be synthesized in same way as the copolymer (VI) of Example 4, except instead of a reagent B2 (e.g., PEG-amidediol), reagent B4 (e.g., PEG-diamine) shown in Table 4 can be used. In copolymer (VII), the value of n can be between about 59 and about 96 and the value of m can be between about 4 and about 41, where m+n=100.
- A copolymer having formula (VIII) can be synthesized and used in practice of the invention.
- The copolymer (VIII) is a product of copolymerization of reagents A2, B1, and C1. A2 can be an amidediol shown in Table 1 where R2 is methylmethylene CH(CH3) and Y is (CH2)4. In other words, A2 can be synthesized by condensation of lactic acid with the 1,4-diamino butane (putrescine).
- B1 can be a PEG-diester-diamine shown in Table 4 where R1 is i-C4H9. In other words, B1 can be synthesized by condensation of leucine with poly(ethylene glycol) having molecular weight of about 2,000 Daltons, which is symbolized by the abbreviation PEG2000.
- C1 can be a dicarboxylic acid shown in Table 5 where R3 is (CH2)8 (sebacic acid, which is also shown in Table 6). In copolymer (VIII), the value of n can be between about 86 and about 99 and the value of m can be between about 1 and about 14, where m+n=100.
- A copolymer having formula (IX) can be synthesized and used in practice of the invention.
- The copolymer (IX) can be synthesized in same way as the copolymer (VIII) of Example 6, except instead of a reagent B1 (PEG-diester-diamine), reagent B2 (PEG-amidediol) shown in Table 4 can be used, where R2 is methylmethylene CH(CH3). In other words, B2 can be synthesized by condensation of lactic acid with PEG-diamine shown as reagent B4 in Table 4. PEG-diamine can be based on poly(ethylene glycol) having molecular weight of about 600 Daltons, which is symbolized by the abbreviation PEG600. In copolymer (IX), the integer value of n can be between about 69 and about 98 and the value of m can be between about 2 and about 31, where m+n=100.
- A copolymer having formula (X) can be synthesized and used in practice of the invention.
- The copolymer (X) can be synthesized in same way as the copolymer (IX) of Example 7, except that a reagent B3 shown in Table 4, (HO—R4—OH), for example, PEG-diol, can be used instead of a reagent B2 (e.g., PEG-amidediol). PEG-diol can be based on poly(ethylene glycol) having molecular weight of about 300 Daltons, which is symbolized by the abbreviation PEG300.
- A2 and B3 reagents can be combined and reacted first to form an A2-B3 moiety, followed by adding a C1 reagent and completing polycondensation. The conditions for the synthesis can be determined by those having ordinary skill in the art. For example, the final step of the reaction (reacting C1 with the A2-B3 moiety) can be conducted in the presence of a coupling agent such as carbodiimide.
- Optionally, instead of a C1 diacid, a dichloride of the diacid can be used, for instance, sebacyl dichloride. In copolymer (X), the value of n can be between about 54 and about 96 and the value of m can be between about 4 and about 46, where m+n=100.
- Alternative versions of the copolymer (X) can be also synthesized to make the copolymer (X) harder. For example, an amino acid with shorter R2 group or a shorter chain diamine (e.g., ethanediamine instead of 1,4-butanediamine) can be used for preparing the reagent A2.
- Other possible methods of increasing the hardness of the copolymer (X) include using a shorter dicarboxylic acid C1 (e.g., adipic acid instead of sebacic acid), or using PEG with lower molecular weight, or reducing the proportion of the PEG-containing units in the overall copolymer (X).
- A copolymer having formula (XI) can be synthesized and used in practice of the invention.
- The copolymer (XI) can be synthesized in same way as the copolymer (X) of Example 9, except that a reagent B4 (such as PEG-diamine) shown in Table 4 can be used instead of a reagent B3 (e.g., PEG-diol). PEG-diamine can be based on poly(ethylene glycol) having molecular weight of about 600 Daltons, which is symbolized by the abbreviation PEG600. In copolymer (XI), the value of n can be between about 3 and about 35, and the value of m can be between about 97 and about 65, where m+n=100.
- A copolymer having formula (XII) can be synthesized and used in practice of the invention.
- The copolymer (XII) can be synthesized in same way as the copolymer (VIII) of Example 6, except that a reagent A3 (diol) shown in Table 1 can be used instead of a reagent A2 (amidediol), where X is (CH2)6. In other words, 1,6-hexanediol can be used as the reagent A3. A poly(ethylene glycol) moiety having molecular weight of about 300 Daltons can comprise a part of copolymer (XII), which is symbolized by the abbreviation PEG300. In copolymer (XII), the value of n can be between about 98 and about 71 and the value of m can be between about 2 and about 29, where m+n=100.
- A copolymer having formula (XIII) can be synthesized and used in practice of the invention.
- The copolymer (XIII) can be synthesized in same way as the copolymer (XII) of Example 10, except that a reagent B2 (e.g., PEG-amidediol) shown in Table 4 can be used instead of a reagent B1 (such as PEG-diester-diamine), where R2 is methylmethylene CH(CH3). In other words, B2 can be synthesized by condensation of lactic acid with PEG-diamine shown as reagent B4 in Table 4. PEG-diamine can be based on poly(ethylene glycol) having molecular weight of about 600 Daltons, which is symbolized by the abbreviation PEG600.
- In copolymer (XIII), the value of n can be between about 98 and about 76 and the value of m can be between about 2 and about 24, where m+n=100.
- A copolymer having formula (XIV) can be synthesized and used in practice of the invention.
- The copolymer (XIV) can be synthesized in same way as the copolymer (XIII) of Example 11, except that a reagent B4 (e.g., PEG-diamine) as shown in Table 4 can be used instead of a reagent B2 (such as PEG-amidediol). PEG-diamine can be based on poly(ethylene glycol) having molecular weight between about 300 and about 2,400 Daltons, for example, about 600 Daltons, which is symbolized by the abbreviation PEG600. Reagent A3 (1,6-hexanediol) and reagent C1 (sebacic acid) can be combined and reacted first to form an A3-C1 moiety, followed by adding reagent B4 and completing polycondensation. To facilitate the formation of the A3-C1 moiety, sebacyl dichloride can be used as the C1 reagent instead of sebacic acid. The conditions for the synthesis can be determined by those having ordinary skill in the art.
- In copolymer (XIV), the value of n can be between about 98 and about 73 and the value of m can be between about 2 and about 27, where m+n=100.
- A copolymer having formula (XV) can be synthesized and used in practice of the invention.
- The copolymer (XV) can be synthesized in same way as the copolymer (VIII) of Example 6, except that a reagent A4 (diamine) shown in Table 1 can be used instead of a reagent A2 (amidediol), where Y is (CH2)4.
- In other words, putrescine can be used as the reagent A4. A poly(ethylene glycol) moiety having molecular weight between about 300 Daltons and about 4,000 Daltons, for example, about 300 Daltons, can comprise a part of copolymer (XV), which is symbolized by the abbreviation PEG300.
- In copolymer (XV), the value of n can be between about 98 and about 73 and the value of m can be between about 2 and about 27, where m+n=100.
- A copolymer having formula (XVI) can be synthesized and used in practice of the invention.
- The copolymer (XVI) can be synthesized in same way as the copolymer (IX) of Example 7, except that a reagent A4 (diamine) shown in Table 1 can be used instead of a reagent A2 (amidediol), where Y is (CH2)4. In other words, putrescine can be used as the reagent A4.
- A poly(ethylene glycol) moiety having molecular weight between about 300 Daltons and about 4,000 Daltons, for example, about 600 Daltons, can comprise a part of copolymer (XVI), which is symbolized by the abbreviation PEG600.
- In copolymer (XVI), the value of n can be between about 98 and about 77, and the value of m can be between about 2 and about 23, where m+n=100.
- A copolymer having formula (XVII) can be synthesized and used in practice of the invention.
- The copolymer (XVII) can be synthesized in same way as the copolymer (X) of Example 8, except that a reagent A4 (diamine) shown in Table 1 can be used instead of a reagent A2 (amidediol), where Y is (CH2)4. In other words, putrescine can be used as the reagent A4.
- A poly(ethylene glycol) moiety having molecular weight between about 300 Daltons and about 4,000 Daltons, for example, about 2,000 Daltons can comprise a part of copolymer (XVII), which is symbolized by the abbreviation PEG2000.
- In copolymer (XVII), the value of n can be between about 995 about 910 the value of m can be between about 5 and about 90, where m+n=1000.
- A copolymer having formula (XVIII) can be synthesized and used in practice of the invention.
- To synthesize the copolymer (XVIII), reagents A1 and C2, can be combined in the molar ratio of about 1:1 and copolymerized. The conditions for the synthesis can be determined by those having ordinary skill in the art. A1 can be a diol-diamine shown in Table 1, where R1 is i-C4H9 and X is (CH2)6. In other words, A1 can be synthesized by condensation of leucine with 1,6-hexanediol. C2 can be a PEG-dicarboxylic acid shown in Table 5, derived from poly(ethylene glycol) having molecular weight of about 1,000 Daltons, which is symbolized by the abbreviation PEG1000. A total molecular weight of the copolymer (XVIII) can be between about 20,000 Daltons and about 50,000 Daltons. The value of the integer p can be between about 14 and about 360.
- A copolymer having formula (XIX) can be synthesized and used in practice of the invention.
- The copolymer (XIX) can be synthesized in same way as the copolymer (XVIII) of Example 16, except that a reagent A2 (amidediol) shown in Table 1 can be used instead of a reagent A1 (diol-diamine), where R2 is methylmethylene CH(CH3), and Y is (CH2)4. In other words, A2 can be synthesized by condensation of lactic acid with putrescine. C2 can be a PEG-dicarboxylic acid shown in Table 5 derived from poly(ethylene glycol) having molecular weight of about 1,000 Daltons, which is symbolized by the abbreviation PEG1000.
- A total molecular weight of the copolymer (XIX) can be between about 20,000 Daltons and about 50,000 Daltons. The value of the integer p can be between about 15 and about 390.
- Co-poly-{[N,N′-adipoyl-bis-(L-alanine)-1,4-butylene diester]37-[N,N′-adipoyl-bis-(L-alanine)-PEG300 diester]67} having formula (XX) can be synthesized and used in practice of the invention. This copolymer belongs to category (A), type A1-B1—C1, described above.
- To synthesize the copolymer (XX), about 41 ml (about 0.293 mole) dry triethylamine in about 75 ml dry solvent N,N′-dimethylacetamide, at room temperature, can be added to a mixture of:
- (a) about 28.64 g (about 0.0497 mole) di-para-toluenesulfonic acid salt of bis-(L-alanine)-1,4-butylene diester;
- (b) about 65.57 g (about 0.0834 mole) di-para-toluenesulphonic acid salt of bis-(L-alanine)-PEG300 diester; and
- (c) about 51.62 g (about 0.1331 mole) di-para-nitrophenyl adipate.
- The mixture can be stirred until full dissolution and then the temperature can be raised to about 80° C. After stirring for about 24 hours, the viscous mixture can be cooled to room temperature, diluted with about 100 ml ethanol, and precipitated into an excess of water. The separated polymer can be thoroughly washed with water, spread thinly onto a TEFLON pan, and dried at room temperature under vacuum (about 70 mm Hg) for about 24 hours.
- As amide bonds are formed in the presence of existing ester bonds, mild conditions need to be used, and this will be understood by those having ordinary skill in the art. For example, polymerization techniques using good leaving groups such as para-nitrophenol or carboxyl groups activated by carbodiimides can be used. In this invention, the range of stoichiometries can be determined by the desired mass content of PEG.
- For example, the final polymer can contain between about 5 mass % and about 50 mass % of PEG. For copolymer (XX), this corresponds to molar ratios of the two blocks of (alanine/butanediol-adipic acid) (A1-C1 blocks) and (alanine/PEG-adipic acid) (B1—C1 blocks) between about 94:6 and about 12:88.
- Co-poly-{[N,N′-sebacyl-1,4-butylene diamide]86-[N,N′-sebacyl-(ED-600) diamide]14} having formula (XXI) can be synthesized and used in practice of the invention. This copolymer belongs to category (B), type (A4-B4—C1), described above.
- In formula (XXI), “ED-600” is an abbreviation symbolizing JEFFAMINE ED-600 polymer described above (see Example 4).
- To synthesize the copolymer (XXI), about 104 ml (about 0.744 mole) dry triethylamine in about 65 ml dry solvent N,N′-dimethylacetamide, at room temperature, can be added to a mixture of:
- (a) about 23.38 g (about 0.266 mole) dry 1,4-diaminobutane; and
- (b) about 25 g (about 0.0417 mole) dry ED-600.
- The mixture can be stirred, under a nitrogen atmosphere at room temperature, until full dissolution. The mixture can be cooled in ice water and about 80.75 g (about 0.338 mole) sebacoyl chloride can be added dropwise with stirring. The solution can be allowed to come to ambient temperature with stirring stirred continued overnight. The viscous mixture can then be precipitated into an excess of water. The separated polymer can be thoroughly washed with water, spread thinly into a TEFLON pan, and dried at room temperature under vacuum (about 70 mm Hg) for about 24 hours.
- As only amide bonds are present, without any other hydrolysable groups, harsher synthetic conditions can be used for this category as understood by those having ordinary skill in the art. For example, acid chlorides can be used. The mass contents of PEG in the final copolymer (XXI) can be between about 5 mass % and about 50 mass %. For copolymer (XXI), this corresponds to molar ratios of the two blocks of diamine-sebacic acid (A4-C1 blocks) and ED-600-sebacic acid (B4—C1 blocks) of between about 97:3 and about 57:43.
- Co-poly-{[N,N′-succinyl-bis-(L-leucine)-1,3-propylene diester]82-[succinyl-PEG600 diester]18} having formula (XXII) can be synthesized and used in practice of the invention. This copolymer belongs to category (C), type (A1-B3—C1), described above.
- To synthesize the copolymer (XXII), about 26.8 g (about 0.227 mole) succinic acid, and about 52.3 g (about 0.454 mole) N-hydroxysuccinimide can be added to about 100 ml dry N,N′-dimethylformamide at room temperature under nitrogen and dissolved with stirring. About 93.67 g (about 0.454 mole) dicyclohexylcarbodiimide (DCC) can be to the mixture added, and the mixture can be allowed to stir for about 16 hours at room temperature.
- The reaction mixture can be filtered through filter paper to remove the urea byproduct, and the solution can be placed into a reaction flask. The following compounds can then be added to the reaction mixture with continued stirring:
- (a) about 55.9 g (about 0.185 mole) the free base of bis-(L-leucine)-1,3-propylene diester; and
- (b) about 25 g (about 0.0417 mole) poly(ethylene glycol) having molecular weight of about 600 Daltons (PEG600).
- The mixture can be stirred at room temperature for about 2 hours and then the temperature can be increased to about 60° C. and stirred for about two more hours. The polymer can precipitated by adding the reaction solution dropwise to about 2 liters of ethyl acetate with stirring. The precipitated polymer can be placed as a thin layer into a TEFLON pan and dried at room temperature under vacuum (about 70 mm Hg) for about 24 hours.
- In this category, both amide and ester bonds are present in the copolymer. Accordingly, mild conditions need to be used, as understood by those having ordinary skill in the art. For example, carboxylate groups activated by carbodiimides can be used or good leaving groups such as para-nitro-phenol can be used. The mass contents of PEG in the final copolymer (XXII) can be between about 5 mass % and about 50 mass %. For copolymer (XXII), this corresponds to molar ratios of the two blocks of leucine/propanediol-succinic acid (A1-C1 blocks) and PEG-diol-succinic acid (B3—C1 blocks) between about 94:6 and about 12:88.
- Co-poly-{[terephthalyl-bis-(D,L-lactate)-1,4-butylene diamide]81-[terphthalyl-bis-(glycolate)-ED600 diamide]19} having formula (XXIII) can be synthesized and used in practice of the invention. This copolymer belongs to category (D), type (A2-B2—C1), described above.
- To synthesize the copolymer (XXIII), the following compounds can be combined in a reaction flask equipped with nitrogen atmosphere, vacuum port, and heating mantle:
- (a) about 0.12 g (about 3.5×10−4 moles) titanium tetrabutoxide;
- (b) about 41.2 g (about 0.178 mole) bis-(D,L-lactate)-1,4-butylene diamide;
- (c) about 29.83 g (about 0.0417 mole) bis-(glycolate)-ED600 diamide, where (ED-600 is as described above; and
- (d) about 42.6 g (about 0.219 mole) dimethyl terephthalate.
- The flask can be sealed and heated to about 180° C. for about 2 hours. After about 2 hours, the pressure can be reduced to about 0.1 Torr, and the solution can be maintained at about 180° C. for about two more hours.
- In this category, only ester bonds present in the copolymer. Amide bonds may, or may not, be present in the reagents. Accordingly, transesterification reactions, under dehydrating conditions, in the presence of the Lewis or Bronsted acid catalysts can be used. Use of acid chlorides is also a viable synthetic technique, because the only hydrolysable bonds that may be present in the reagents are stable amide bonds. The mass contents of PEG in the final copolymer (XXIII) can be between about 5 mass % and about 50 mass %. For copolymer (XXIII), this corresponds to molar ratios of the two blocks of (A2-C1 blocks) (B2—C1 blocks) between about 97:3 and about 49:51.
- A first composition can be prepared, the composition including:
- (a) between about 1.0 mass % and about 15 mass %, for example, about 2.0 mass % co-poly-{[N,N′-sebacoyl-bis-(L-leucine)-1,6-hexylene diester]75-[N,N′-sebacoyl-L-lysine benzyl ester]25};
- (b) between about 0.1 mass % and about 2.0 mass %, for example, about 0.5 mass % paclitaxel; and
- (c) the balance, a solvent blend of ethanol and 1,1,2-trichloroethane, where the mass ratio between ethanol and 1,1,2-trichloroethane can be about 1:1.
- The first composition can be applied onto the surface of bare 12 mm VISION stent (available from Guidant Corporation). Coating can be sprayed and dried to form a drug-polymer layer. A spray coater can be used having a 0.014 round nozzle maintained at ambient temperature with a feed pressure of about 2.5 psi (0.17 atm) and an atomization pressure of about 15 psi (1.02 atm). Coating can be applied at about 20 μg per pass. Between the passes the stent can be dried for about 10 seconds in a flowing air stream at about 50° C. About 270 μg of wet coating can be applied. The stent can be baked at about 50° C. for about one hour, yielding a drug-polymer layer containing about 250 μg of dry coating.
- A second composition can be prepared by mixing the following components:
- (a) between about 1.0 mass % and about 15 mass %, for example, about 2.0 mass % copolymer (XX) described in Example 18; and
- (b) the balance, a solvent blend of ethanol and 1,1,2-trichloroethane, where the mass ratio between ethanol and 1,1,2-trichloroethane can be about 1:1.
- The second composition can be applied onto the dry drug-polymer layer to form the topcoat layer. The same spraying technique and equipment can be used for the applying the topcoat layer as described for the drug-polymer layer. About 120 μg of wet coating can be applied, followed by drying, e.g., baking at about 50° C. for about one hour, yielding about 100 μg of a biocompatible topcoat layer.
- A first composition can be prepared by mixing the following components:
- (a) between about 1.0 mass % and about 15 mass %, for example, about 2.0 mass % copolymer co-poly-{[N,N′-sebacoyl-bis-(L-leucine)-1,6-hexylene diester]75-[N,N′-sebacoyl-L-lysine-4-amino-TEMPO amide]25}; and
- (b) the balance, 100% ethanol.
- The first composition can be applied onto the surface of bare 12 mm VISION stent using equipment and coating technique described in Example 22. About 120 μg of wet coating can be applied. The stents can be baked at about 50° C. for about one hour, yielding about 100 μg of a dry primer layer. The copolymer forming the primer layer includes 4-amino-TEMPO (4-amino-2,2′,6,6′-tetramethylpiperidine-1-oxy) moiety attached to lysine via an amide linkage.
- A second composition can be prepared by mixing the following components:
- (a) between about 0.1 mass % and about 3.0 mass %, for example, about 2.0 mass % EVEROLIMUS; and
- (b) the balance, 100% ethanol.
- The second composition can be applied onto the dry primer layer, to form the pure drug layer. The same spraying technique and equipment can be used for the applying the drug layer as described above. Coating can be applied at about 20 μg per pass. Between the passes the stent can be dried for about 10 seconds in a flowing air stream at about 50° C. About 110 μg of neat drug coating can be applied. The stent can be baked at about 50° C. for about one hour, yielding a pure dry drug-layer containing about 100 μg of dry coating.
- A third composition can be prepared by mixing the following components:
- (a) between about 0.5 mass % and about 10 mass %, for example, about 1.0 mass % copolymer (XX) described in Example 18;
- (b) between about 0.5 mass % and about 10 mass %, for example, about 1.0 mass % co-poly-{[N,N′-sebacoyl-bis-(L-leucine)-1,6-hexylene diester]75-[N,N′-sebacoyl-L-lysine benzyl ester]25}described in Example 22; and
- (c) the balance, 100% ethanol.
- The third composition can be applied onto the dry pure drug layer to form the topcoat layer. The same spraying technique and equipment can be used for the applying the topcoat layer as described above. About 440 μg of wet coating can be applied, followed by drying, e.g., baking at about 50° C. for about one hour, yielding about 400 μg of a biocompatible topcoat layer, which can also control the release of the drug.
- While particular embodiments of the present invention have been shown and described, it will be obvious to those skilled in the art that changes and modifications can be made without departing from this invention in its broader aspects. Therefore, the appended claims are to encompass within their scope all such changes and modifications as fall within the true spirit and scope of this invention.
Claims (22)
1.-20. (canceled)
21. A method for fabricating a medical article, the method—including synthesizing a copolymer and forming a coating based on the copolymer on at least a portion of an implantable substrate, the synthesizing of the copolymer including reacting a first reagent with a second reagent and with a third reagent, wherein:
(a) the first reagent is selected from a group consisting of compounds having formulae (1), (2), (3), and (4):
(b) the second reagent is selected from a group consisting of compounds having formulae (5), (6), (7), and (8):
wherein:
R1 is hydrogen, methyl, iso-propyl, sec-butyl; iso-butyl, or benzyl group;
R2 is methylene, methylmethylene, n-propylene, iso-propylene, ethylmethylene, n-butylene, iso-butylene, sec-butylene, or n-amylene group;
R3 is a straight chained or branched aliphatic alkylene group CnH2n, wherein n is an integer between 2 and 12;
R4 is a moiety derived from a compound selected from a group consisting of poly(ethylene glycol), poly(propylene glycol), random poly(ethylene glycol-co-propylene glycol), poly(ethylene glycol)-block-poly(propylene glycol), hyaluronic acid, poly(2-hydroxyethyl methacrylate), poly(3-hydroxypropylmethacrylamide), poly(styrene sulfonate), poly(vinyl pyrrolidone), and cellulosics;
X is a straight chained or branched aliphatic alkylene group CnH2n, wherein n is an integer between 2 and 12;
Y is a straight chained or branched aliphatic alkylene group CnH2n, wherein n is 1, 2, or 5.
22. The method of claim 21 , wherein the implantable substrate is a stent.
23. The method of claim 21 , wherein the molar ratio between the first reagent, the second reagent, and the third reagent is about 1:1:2.
24. The method of claim 21 , wherein the compound of formula (1) is a diol-diamine, the diol-diamine is a product of condensation of an amino acid and a diol.
25. The method of claim 24 , wherein the amino acid has the formula (10):
H2N—CHR1—COOH. (10)
H2N—CHR1—COOH. (10)
26. The method of claim 24 , wherein the amino acid is selected from a group consisting of glycine, alanine, valine, isoleucine, leucine, and phenyl alanine.
27. The method of claim 24 , wherein a diol is selected from a group consisting of ethylene glycol, 1,3-propanediol, 1,4-butane diol, 1,5-pentanediol, 1,6-hexanediol, 1,7-heptanediol, 1,8-octanediol, 1,9-nonanediol, 1,10-decanediol, 1,11-undecanediol, and 1,12-dodecanediol.
28. The method of claim 21 , wherein the compound of formula (2) is an amidediol, the amidediol is a product of condensation of a hydroxy acid and a diamine.
29. The method of claim 28 , wherein the hydroxy acid has the formula (11):
HO—R2—COOH. (11)
HO—R2—COOH. (11)
30. The method of claim 28 , wherein the hydroxy acid is selected from a group consisting of glycolic acid, lactic acid, β-hydroxybutyric acid, α-hydroxyvaleric acid, and ε-hydroxycaproic acid.
31. The method of claim 28 , wherein the diamine is selected from a group consisting of putrescine, 1,2-ethanediamine, and cadavarene.
32. The method of claim 21 , wherein the compound of formula (3) is selected from a group consisting of ethylene glycol, 1,3-propanediol, 1,4-butane diol, 1,5-pentanediol, 1,6-hexanediol, 1,7-heptanediol, 1,8-octanediol, 1,9-nonanediol, 1,10-decanediol, 1,11-undecanediol, and 1,12-dodecanediol.
33. The method of claim 21 , wherein the compound of formula (4) is selected from a group consisting of putrescine, 1,2-ethanediamine, and cadavarene.
34. The method of claim 21 , wherein the compound of formula (5) is a PEG-diester-diamine conjugate, the conjugate is a product of condensation of an amino acid and poly(ethylene glycol).
35. The method of claim 34 , wherein the amino acid has the formula (10):
H2N—CHR1—COOH. (10)
H2N—CHR1—COOH. (10)
36. The method of claim 34 , wherein the amino acid is selected from a group consisting of glycine, alanine, valine, isoleucine, leucine, phenyl alanine, tyrosine, serine, and glutamic acid.
37. The method of claim 21 , wherein the compound of formula (6) is a PEG-amidediol conjugate, the conjugate is a product of condensation of a hydroxy acid and PEG-diamine.
38. The method of claim 37 , wherein the hydroxy acid has the formula (11):
HO—R2—COOH. (11)
HO—R2—COOH. (11)
39. The method of claim 37 , wherein the hydroxy acid is selected from a group consisting of glycolic acid, lactic acid, β-hydroxybutyric acid, α-hydroxyvaleric acid, and ε-hydroxycaproic acid.
40. A method for fabricating a medical article, the method including synthesizing a copolymer and forming a coating based on the copolymer on at least a portion of an implantable substrate, wherein the copolymer has a general formula (12) or (13):
-[M-P]m-[M-Q]n- (12)
-[M1-P]p- (13)
-[M-P]m-[M-Q]n- (12)
-[M1-P]p- (13)
wherein:
M is a moiety represented by the structure having the formula (14)
P is a moiety selected from a group consisting of structures having the formulae (15), (16), (17), and (18):
Q is a moiety selected from a group consisting of structures having the formulae (19), (20), and (21)
R1 is hydrogen, methyl, iso-propyl, sec-butyl; iso-butyl, or benzyl group;
R2 is methylene, methylmethylene, n-propylene, iso-propylene, ethylmethylene, n-butylene, iso-butylene, sec-butylene, or n-amylene group;
R3 is a straight chained or branched aliphatic alkylene group CnH2n, wherein n is an integer between 2 and 12;
X is a straight chained or branched aliphatic alkylene group CnH2n, wherein n is an integer between 2 and 12;
Y is a straight chained or branched aliphatic alkylene group CnH2n, wherein n is 1, 2, or 5; and
Z is a moiety derived from a compound selected from a group consisting of poly(ethylene glycol), poly(propylene glycol), random poly(ethylene glycol-co-propylene glycol), poly(ethylene glycol)-block-poly(propylene glycol), hyaluronic acid, poly(2-hydroxyethyl methacrylate), poly(3-hydroxypropylmethacrylamide), poly(styrene sulfonate), poly(vinyl pyrrolidone, and cellulosics; and
m, n, and p are integers where the value of m is between 5 and 1,800, the value of n is between 1 and 800 and the value of p is between 4 and 1,500.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14/168,903 US20140147687A1 (en) | 2004-03-16 | 2014-01-30 | Biologically absorbable coating for implantable devices based on copolymers having ester bonds and methods of fabricating the same |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/805,036 US8685431B2 (en) | 2004-03-16 | 2004-03-16 | Biologically absorbable coatings for implantable devices based on copolymers having ester bonds and methods for fabricating the same |
US14/168,903 US20140147687A1 (en) | 2004-03-16 | 2014-01-30 | Biologically absorbable coating for implantable devices based on copolymers having ester bonds and methods of fabricating the same |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/805,036 Continuation US8685431B2 (en) | 2004-03-16 | 2004-03-16 | Biologically absorbable coatings for implantable devices based on copolymers having ester bonds and methods for fabricating the same |
Publications (1)
Publication Number | Publication Date |
---|---|
US20140147687A1 true US20140147687A1 (en) | 2014-05-29 |
Family
ID=34965777
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/805,036 Expired - Fee Related US8685431B2 (en) | 2004-03-16 | 2004-03-16 | Biologically absorbable coatings for implantable devices based on copolymers having ester bonds and methods for fabricating the same |
US14/168,806 Abandoned US20140147686A1 (en) | 2004-03-16 | 2014-01-30 | Biologically absorbable coating for implantable devices based on copolymers having ester bonds and methods of fabricating the same |
US14/168,903 Abandoned US20140147687A1 (en) | 2004-03-16 | 2014-01-30 | Biologically absorbable coating for implantable devices based on copolymers having ester bonds and methods of fabricating the same |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/805,036 Expired - Fee Related US8685431B2 (en) | 2004-03-16 | 2004-03-16 | Biologically absorbable coatings for implantable devices based on copolymers having ester bonds and methods for fabricating the same |
US14/168,806 Abandoned US20140147686A1 (en) | 2004-03-16 | 2014-01-30 | Biologically absorbable coating for implantable devices based on copolymers having ester bonds and methods of fabricating the same |
Country Status (4)
Country | Link |
---|---|
US (3) | US8685431B2 (en) |
EP (1) | EP1789105A2 (en) |
JP (1) | JP2007529270A (en) |
WO (1) | WO2005089824A2 (en) |
Families Citing this family (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2178541C (en) | 1995-06-07 | 2009-11-24 | Neal E. Fearnot | Implantable medical device |
US20060177416A1 (en) | 2003-10-14 | 2006-08-10 | Medivas, Llc | Polymer particle delivery compositions and methods of use |
US7435788B2 (en) | 2003-12-19 | 2008-10-14 | Advanced Cardiovascular Systems, Inc. | Biobeneficial polyamide/polyethylene glycol polymers for use with drug eluting stents |
US20050208093A1 (en) | 2004-03-22 | 2005-09-22 | Thierry Glauser | Phosphoryl choline coating compositions |
US20050288481A1 (en) | 2004-04-30 | 2005-12-29 | Desnoyer Jessica R | Design of poly(ester amides) for the control of agent-release from polymeric compositions |
US8603634B2 (en) | 2004-10-27 | 2013-12-10 | Abbott Cardiovascular Systems Inc. | End-capped poly(ester amide) copolymers |
US7390497B2 (en) | 2004-10-29 | 2008-06-24 | Advanced Cardiovascular Systems, Inc. | Poly(ester amide) filler blends for modulation of coating properties |
US7419504B2 (en) | 2004-12-27 | 2008-09-02 | Advanced Cardiovascular Systems, Inc. | Poly(ester amide) block copolymers |
US8377462B2 (en) * | 2005-07-29 | 2013-02-19 | Advanced Cardiovascular Systems, Inc. | PEA-TEMPO/PEA-BZ coatings for controlled delivery of drug from implantable medical devices |
JP5178520B2 (en) | 2005-09-22 | 2013-04-10 | メディバス エルエルシー | Solid polymer delivery compositions and methods of use thereof |
JP5192384B2 (en) | 2005-09-22 | 2013-05-08 | メディバス エルエルシー | Bis- (α-amino) -diol-diester-containing poly (ester amide) and poly (ester urethane) compositions and methods of use |
US7910152B2 (en) | 2006-02-28 | 2011-03-22 | Advanced Cardiovascular Systems, Inc. | Poly(ester amide)-based drug delivery systems with controlled release rate and morphology |
US8658210B2 (en) | 2006-04-17 | 2014-02-25 | Advanced Cardiovascular Systems, Inc. | Polyesteramide platform for site specific drug delivery |
US8069814B2 (en) | 2006-05-04 | 2011-12-06 | Advanced Cardiovascular Systems, Inc. | Stent support devices |
US20090258028A1 (en) * | 2006-06-05 | 2009-10-15 | Abbott Cardiovascular Systems Inc. | Methods Of Forming Coatings For Implantable Medical Devices For Controlled Release Of A Peptide And A Hydrophobic Drug |
US8323676B2 (en) * | 2008-06-30 | 2012-12-04 | Abbott Cardiovascular Systems Inc. | Poly(ester-amide) and poly(amide) coatings for implantable medical devices for controlled release of a protein or peptide and a hydrophobic drug |
US20080124372A1 (en) | 2006-06-06 | 2008-05-29 | Hossainy Syed F A | Morphology profiles for control of agent release rates from polymer matrices |
US7771739B2 (en) * | 2006-06-30 | 2010-08-10 | Abbott Cardiovascular Systems Inc. | Implantable medical devices comprising semi-crystalline poly(ester-amide) |
US20090181063A1 (en) * | 2006-07-13 | 2009-07-16 | Michael Huy Ngo | Implantable medical device comprising a pro-healing poly(ester-amide) |
US8685430B1 (en) | 2006-07-14 | 2014-04-01 | Abbott Cardiovascular Systems Inc. | Tailored aliphatic polyesters for stent coatings |
CA2656681C (en) | 2006-08-04 | 2014-04-22 | Nerites Corporation | Biomimetic compounds and synthetic methods therefor |
US8383092B2 (en) * | 2007-02-16 | 2013-02-26 | Knc Ner Acquisition Sub, Inc. | Bioadhesive constructs |
US10155881B2 (en) * | 2007-05-30 | 2018-12-18 | Abbott Cardiovascular Systems Inc. | Substituted polycaprolactone for coating |
US8252361B2 (en) * | 2007-06-05 | 2012-08-28 | Abbott Cardiovascular Systems Inc. | Implantable medical devices for local and regional treatment |
US9737638B2 (en) | 2007-06-20 | 2017-08-22 | Abbott Cardiovascular Systems, Inc. | Polyester amide copolymers having free carboxylic acid pendant groups |
US20090004243A1 (en) | 2007-06-29 | 2009-01-01 | Pacetti Stephen D | Biodegradable triblock copolymers for implantable devices |
JP2010536884A (en) * | 2007-08-23 | 2010-12-02 | メディバス エルエルシー | Biodegradable polymer gene transfer composition containing cationic alpha amino acid |
US9814553B1 (en) | 2007-10-10 | 2017-11-14 | Abbott Cardiovascular Systems Inc. | Bioabsorbable semi-crystalline polymer for controlling release of drug from a coating |
US20090104241A1 (en) * | 2007-10-23 | 2009-04-23 | Pacetti Stephen D | Random amorphous terpolymer containing lactide and glycolide |
US20090306120A1 (en) * | 2007-10-23 | 2009-12-10 | Florencia Lim | Terpolymers containing lactide and glycolide |
US8642062B2 (en) | 2007-10-31 | 2014-02-04 | Abbott Cardiovascular Systems Inc. | Implantable device having a slow dissolving polymer |
US8128983B2 (en) * | 2008-04-11 | 2012-03-06 | Abbott Cardiovascular Systems Inc. | Coating comprising poly(ethylene glycol)-poly(lactide-glycolide-caprolactone) interpenetrating network |
US20090297584A1 (en) * | 2008-04-18 | 2009-12-03 | Florencia Lim | Biosoluble coating with linear over time mass loss |
US8916188B2 (en) | 2008-04-18 | 2014-12-23 | Abbott Cardiovascular Systems Inc. | Block copolymer comprising at least one polyester block and a poly (ethylene glycol) block |
US20090285873A1 (en) * | 2008-04-18 | 2009-11-19 | Abbott Cardiovascular Systems Inc. | Implantable medical devices and coatings therefor comprising block copolymers of poly(ethylene glycol) and a poly(lactide-glycolide) |
US8889172B1 (en) | 2008-04-30 | 2014-11-18 | Abbott Cardiovascular Systems Inc. | Amorphous or semi-crystalline poly(ester amide) polymer with a high glass transition temperature |
US8697113B2 (en) * | 2008-05-21 | 2014-04-15 | Abbott Cardiovascular Systems Inc. | Coating comprising a terpolymer comprising caprolactone and glycolide |
US8765162B2 (en) | 2008-06-30 | 2014-07-01 | Abbott Cardiovascular Systems Inc. | Poly(amide) and poly(ester-amide) polymers and drug delivery particles and coatings containing same |
US20100047319A1 (en) * | 2008-08-21 | 2010-02-25 | Michael Huy Ngo | Biodegradable Poly(Ester-Amide) And Poly(Amide) Coatings For Implantable Medical Devices With Enhanced Bioabsorption Times |
US8642063B2 (en) | 2008-08-22 | 2014-02-04 | Cook Medical Technologies Llc | Implantable medical device coatings with biodegradable elastomer and releasable taxane agent |
US8697110B2 (en) | 2009-05-14 | 2014-04-15 | Abbott Cardiovascular Systems Inc. | Polymers comprising amorphous terpolymers and semicrystalline blocks |
WO2011145383A1 (en) * | 2010-05-19 | 2011-11-24 | 三菱瓦斯化学株式会社 | Polyester amide compound |
US9320826B2 (en) | 2010-11-09 | 2016-04-26 | Kensey Nash Corporation | Adhesive compounds and methods use for hernia repair |
US9873765B2 (en) | 2011-06-23 | 2018-01-23 | Dsm Ip Assets, B.V. | Biodegradable polyesteramide copolymers for drug delivery |
CA2839526A1 (en) | 2011-06-23 | 2012-12-27 | Dsm Ip Assets B.V. | Micro- or nanoparticles comprising a biodegradable polyesteramide copolymer for use in the delivery of bioactive agents |
CA2866330A1 (en) * | 2012-05-30 | 2013-12-05 | Boston Scientific Scimed, Inc. | Injectable biodegradable particles for controlled therapeutic agent release |
CA2969171C (en) | 2014-12-18 | 2023-12-12 | Dsm Ip Assets B.V. | Drug delivery system for delivery of acid sensitive drugs |
CN105797220B (en) * | 2014-12-31 | 2020-07-31 | 先健科技(深圳)有限公司 | Degradable iron-based alloy stent |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5358677A (en) * | 1992-03-17 | 1994-10-25 | United States Surgical Corporation | Methods of forming bioabsorbable objects from polyvinyl alcohol |
DE19753532A1 (en) * | 1997-12-03 | 1999-06-10 | Bayer Ag | Easily produced random polyether-ester-amides with high water vapor permeability, suitable for film extrusion |
US6344535B1 (en) * | 1997-12-03 | 2002-02-05 | Bayer Aktiengesellschaft | Polyether ester amides |
US20020015720A1 (en) * | 2000-01-11 | 2002-02-07 | Ramaz Katsarava | Polymer blends as biodegradable matrices for preparing biocomposites |
US20020065553A1 (en) * | 2000-11-28 | 2002-05-30 | Scimed Life System, Inc. | Method for manufacturing a medical device having a coated portion by laser ablation |
EP1236757A1 (en) * | 1999-09-30 | 2002-09-04 | Sekisui Chemical Co., Ltd. | Thermoplastic elastomer, use thereof, and process for producing the same |
Family Cites Families (263)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR732895A (en) | 1932-10-18 | 1932-09-25 | Consortium Elektrochem Ind | Articles spun in polyvinyl alcohol |
US2386454A (en) | 1940-11-22 | 1945-10-09 | Bell Telephone Labor Inc | High molecular weight linear polyester-amides |
US3849514A (en) | 1967-11-17 | 1974-11-19 | Eastman Kodak Co | Block polyester-polyamide copolymers |
BE773738A (en) * | 1970-10-13 | 1972-01-31 | Snam Progetti | PROCESS FOR MANUFACTURING MONOMERS THAT CAN BE USED IN THE SYNTHESIS OF REGULAR POLYESTER-AMIDS AND POLYESTER-AMIDES OBTAINED BY THIS PROCESS |
US3773737A (en) | 1971-06-09 | 1973-11-20 | Sutures Inc | Hydrolyzable polymers of amino acid and hydroxy acids |
US4329383A (en) | 1979-07-24 | 1982-05-11 | Nippon Zeon Co., Ltd. | Non-thrombogenic material comprising substrate which has been reacted with heparin |
US4226243A (en) | 1979-07-27 | 1980-10-07 | Ethicon, Inc. | Surgical devices of polyesteramides derived from bis-oxamidodiols and dicarboxylic acids |
SU790725A1 (en) | 1979-07-27 | 1983-01-23 | Ордена Ленина Институт Элементоорганических Соединений Ан Ссср | Process for preparing alkylaromatic polyimides |
SU872531A1 (en) | 1979-08-07 | 1981-10-15 | Институт Физиологии Им.И.С.Бериташвили Ан Гсср | Method of producing polyurethans |
SU811750A1 (en) | 1979-08-07 | 1983-09-23 | Институт Физиологии Им.С.И.Бериташвили | Bis-bicarbonates of aliphatic diols as monomers for preparing polyurethanes and process for producing the same |
SU876663A1 (en) | 1979-11-11 | 1981-10-30 | Институт Физиологии Им. Академика И.С.Бериташвили Ан Гсср | Method of producing polyarylates |
US4529792A (en) | 1979-12-17 | 1985-07-16 | Minnesota Mining And Manufacturing Company | Process for preparing synthetic absorbable poly(esteramides) |
SU1016314A1 (en) | 1979-12-17 | 1983-05-07 | Институт Физиологии Им.И.С.Бериташвили | Process for producing polyester urethanes |
US4343931A (en) | 1979-12-17 | 1982-08-10 | Minnesota Mining And Manufacturing Company | Synthetic absorbable surgical devices of poly(esteramides) |
SU905228A1 (en) | 1980-03-06 | 1982-02-15 | Институт Физиологии Им. Акад.И.С. Бериташвили Ан Гсср | Method for preparing thiourea |
US4304767A (en) | 1980-05-15 | 1981-12-08 | Sri International | Polymers of di- (and higher functionality) ketene acetals and polyols |
SU1293518A1 (en) | 1985-04-11 | 1987-02-28 | Тбилисский зональный научно-исследовательский и проектный институт типового и экспериментального проектирования жилых и общественных зданий | Installation for testing specimen of cross-shaped structure |
US4656242A (en) | 1985-06-07 | 1987-04-07 | Henkel Corporation | Poly(ester-amide) compositions |
US4733665C2 (en) | 1985-11-07 | 2002-01-29 | Expandable Grafts Partnership | Expandable intraluminal graft and method and apparatus for implanting an expandable intraluminal graft |
US4611051A (en) | 1985-12-31 | 1986-09-09 | Union Camp Corporation | Novel poly(ester-amide) hot-melt adhesives |
US4882168A (en) | 1986-09-05 | 1989-11-21 | American Cyanamid Company | Polyesters containing alkylene oxide blocks as drug delivery systems |
JPH0696023B2 (en) | 1986-11-10 | 1994-11-30 | 宇部日東化成株式会社 | Artificial blood vessel and method for producing the same |
US4760112A (en) * | 1986-12-01 | 1988-07-26 | General Electric Company | Thermoplastic polyetherimide ester polymers exhibiting high flexural modulus |
US5721131A (en) | 1987-03-06 | 1998-02-24 | United States Of America As Represented By The Secretary Of The Navy | Surface modification of polymers with self-assembled monolayers that promote adhesion, outgrowth and differentiation of biological cells |
US4800882A (en) | 1987-03-13 | 1989-01-31 | Cook Incorporated | Endovascular stent and delivery system |
US6387379B1 (en) | 1987-04-10 | 2002-05-14 | University Of Florida | Biofunctional surface modified ocular implants, surgical instruments, medical devices, prostheses, contact lenses and the like |
US4894231A (en) | 1987-07-28 | 1990-01-16 | Biomeasure, Inc. | Therapeutic agent delivery system |
US4886062A (en) | 1987-10-19 | 1989-12-12 | Medtronic, Inc. | Intravascular radially expandable stent and method of implant |
US5019096A (en) | 1988-02-11 | 1991-05-28 | Trustees Of Columbia University In The City Of New York | Infection-resistant compositions, medical devices and surfaces and methods for preparing and using same |
JP2561309B2 (en) | 1988-03-28 | 1996-12-04 | テルモ株式会社 | Medical material and manufacturing method thereof |
US4931287A (en) | 1988-06-14 | 1990-06-05 | University Of Utah | Heterogeneous interpenetrating polymer networks for the controlled release of drugs |
US5328471A (en) | 1990-02-26 | 1994-07-12 | Endoluminal Therapeutics, Inc. | Method and apparatus for treatment of focal disease in hollow tubular organs and other tissue lumens |
US4977901A (en) | 1988-11-23 | 1990-12-18 | Minnesota Mining And Manufacturing Company | Article having non-crosslinked crystallized polymer coatings |
IL90193A (en) | 1989-05-04 | 1993-02-21 | Biomedical Polymers Int | Polurethane-based polymeric materials and biomedical articles and pharmaceutical compositions utilizing the same |
US5272012A (en) | 1989-06-23 | 1993-12-21 | C. R. Bard, Inc. | Medical apparatus having protective, lubricious coating |
US5971954A (en) | 1990-01-10 | 1999-10-26 | Rochester Medical Corporation | Method of making catheter |
KR920703028A (en) | 1990-01-30 | 1992-12-17 | 에프.지.엠.헤르만스 | Products for controlling the emission of active substances, including hollow spaces which are enclosed in walls and wholly or partially filled with one or more active substances |
US5300295A (en) | 1990-05-01 | 1994-04-05 | Mediventures, Inc. | Ophthalmic drug delivery with thermoreversible polyoxyalkylene gels adjustable for pH |
US5292516A (en) | 1990-05-01 | 1994-03-08 | Mediventures, Inc. | Body cavity drug delivery with thermoreversible gels containing polyoxyalkylene copolymers |
US5298260A (en) | 1990-05-01 | 1994-03-29 | Mediventures, Inc. | Topical drug delivery with polyoxyalkylene polymer thermoreversible gels adjustable for pH and osmolality |
US5306501A (en) | 1990-05-01 | 1994-04-26 | Mediventures, Inc. | Drug delivery by injection with thermoreversible gels containing polyoxyalkylene copolymers |
WO1991017724A1 (en) | 1990-05-17 | 1991-11-28 | Harbor Medical Devices, Inc. | Medical device polymer |
ATE123658T1 (en) | 1990-06-15 | 1995-06-15 | Cortrak Medical Inc | DEVICE FOR DISPENSING MEDICATIONS. |
CA2038605C (en) | 1990-06-15 | 2000-06-27 | Leonard Pinchuk | Crack-resistant polycarbonate urethane polymer prostheses and the like |
US6060451A (en) | 1990-06-15 | 2000-05-09 | The National Research Council Of Canada | Thrombin inhibitors based on the amino acid sequence of hirudin |
US5112457A (en) | 1990-07-23 | 1992-05-12 | Case Western Reserve University | Process for producing hydroxylated plasma-polymerized films and the use of the films for enhancing the compatiblity of biomedical implants |
US5455040A (en) | 1990-07-26 | 1995-10-03 | Case Western Reserve University | Anticoagulant plasma polymer-modified substrate |
US5163952A (en) | 1990-09-14 | 1992-11-17 | Michael Froix | Expandable polymeric stent with memory and delivery apparatus and method |
US5258020A (en) | 1990-09-14 | 1993-11-02 | Michael Froix | Method of using expandable polymeric stent with memory |
US6248129B1 (en) | 1990-09-14 | 2001-06-19 | Quanam Medical Corporation | Expandable polymeric stent with memory and delivery apparatus and method |
US5462990A (en) | 1990-10-15 | 1995-10-31 | Board Of Regents, The University Of Texas System | Multifunctional organic polymers |
GB9027793D0 (en) | 1990-12-21 | 1991-02-13 | Ucb Sa | Polyester-amides containing terminal carboxyl groups |
DE4107283A1 (en) * | 1991-03-07 | 1992-09-10 | Henkel Kgaa | SPINNING PREPARATIONS FOR SYNTHETIC FILAMENT FIBERS |
HU222501B1 (en) | 1991-06-28 | 2003-07-28 | Endorecherche Inc. | Controlled release pharmaceutical composition containing mpa or mga and process for its preparation |
US5330768A (en) | 1991-07-05 | 1994-07-19 | Massachusetts Institute Of Technology | Controlled drug delivery using polymer/pluronic blends |
US5573934A (en) | 1992-04-20 | 1996-11-12 | Board Of Regents, The University Of Texas System | Gels for encapsulation of biological materials |
US5599352A (en) | 1992-03-19 | 1997-02-04 | Medtronic, Inc. | Method of making a drug eluting stent |
GB9206736D0 (en) | 1992-03-27 | 1992-05-13 | Sandoz Ltd | Improvements of organic compounds and their use in pharmaceutical compositions |
US5219980A (en) | 1992-04-16 | 1993-06-15 | Sri International | Polymers biodegradable or bioerodiable into amino acids |
US5417981A (en) | 1992-04-28 | 1995-05-23 | Terumo Kabushiki Kaisha | Thermoplastic polymer composition and medical devices made of the same |
DE4224401A1 (en) | 1992-07-21 | 1994-01-27 | Pharmatech Gmbh | New biodegradable homo- and co-polymer(s) for pharmaceutical use - produced by polycondensation of prod. from heterolytic cleavage of aliphatic polyester with functionalised (cyclo)aliphatic cpd. |
FR2699168B1 (en) | 1992-12-11 | 1995-01-13 | Rhone Poulenc Chimie | Method of treating a material comprising a polymer by hydrolysis. |
EP0604022A1 (en) | 1992-12-22 | 1994-06-29 | Advanced Cardiovascular Systems, Inc. | Multilayered biodegradable stent and method for its manufacture |
US5824048A (en) | 1993-04-26 | 1998-10-20 | Medtronic, Inc. | Method for delivering a therapeutic substance to a body lumen |
US5464650A (en) | 1993-04-26 | 1995-11-07 | Medtronic, Inc. | Intravascular stent and method |
US20020055710A1 (en) | 1998-04-30 | 2002-05-09 | Ronald J. Tuch | Medical device for delivering a therapeutic agent and method of preparation |
JPH0767895A (en) | 1993-06-25 | 1995-03-14 | Sumitomo Electric Ind Ltd | Antimicrobial artificial blood vessel and suture yarn for antimicrobial operation |
US5886026A (en) | 1993-07-19 | 1999-03-23 | Angiotech Pharmaceuticals Inc. | Anti-angiogenic compositions and methods of use |
EG20321A (en) | 1993-07-21 | 1998-10-31 | Otsuka Pharma Co Ltd | Medical material and process for producing the same |
GB2281161B (en) | 1993-08-04 | 1997-05-28 | Fulcrum Communications Limited | Optical data communications networks |
DE4327024A1 (en) | 1993-08-12 | 1995-02-16 | Bayer Ag | Thermoplastically processable and biodegradable aliphatic polyesteramides |
US5380299A (en) | 1993-08-30 | 1995-01-10 | Med Institute, Inc. | Thrombolytic treated intravascular medical device |
WO1995010989A1 (en) | 1993-10-19 | 1995-04-27 | Scimed Life Systems, Inc. | Intravascular stent pump |
US5723004A (en) | 1993-10-21 | 1998-03-03 | Corvita Corporation | Expandable supportive endoluminal grafts |
WO1995019796A1 (en) | 1994-01-21 | 1995-07-27 | Brown University Research Foundation | Biocompatible implants |
US6051576A (en) | 1994-01-28 | 2000-04-18 | University Of Kentucky Research Foundation | Means to achieve sustained release of synergistic drugs by conjugation |
AU710504B2 (en) | 1994-03-15 | 1999-09-23 | Brown University Research Foundation | Polymeric gene delivery system |
US5567410A (en) | 1994-06-24 | 1996-10-22 | The General Hospital Corporation | Composotions and methods for radiographic imaging |
US5670558A (en) | 1994-07-07 | 1997-09-23 | Terumo Kabushiki Kaisha | Medical instruments that exhibit surface lubricity when wetted |
US5788979A (en) | 1994-07-22 | 1998-08-04 | Inflow Dynamics Inc. | Biodegradable coating with inhibitory properties for application to biocompatible materials |
US5516881A (en) | 1994-08-10 | 1996-05-14 | Cornell Research Foundation, Inc. | Aminoxyl-containing radical spin labeling in polymers and copolymers |
US5578073A (en) | 1994-09-16 | 1996-11-26 | Ramot Of Tel Aviv University | Thromboresistant surface treatment for biomaterials |
US5649977A (en) | 1994-09-22 | 1997-07-22 | Advanced Cardiovascular Systems, Inc. | Metal reinforced polymer stent |
US5485496A (en) | 1994-09-22 | 1996-01-16 | Cornell Research Foundation, Inc. | Gamma irradiation sterilizing of biomaterial medical devices or products, with improved degradation and mechanical properties |
FR2724938A1 (en) | 1994-09-28 | 1996-03-29 | Lvmh Rech | POLYMERS FUNCTIONALIZED BY AMINO ACIDS OR AMINO ACID DERIVATIVES, THEIR USE AS SURFACTANTS, IN PARTICULAR, IN COSMETIC COMPOSITIONS AND IN PARTICULAR NAIL POLISH. |
WO1996011671A1 (en) | 1994-10-12 | 1996-04-25 | Focal, Inc. | Targeted delivery via biodegradable polymers |
US5637113A (en) | 1994-12-13 | 1997-06-10 | Advanced Cardiovascular Systems, Inc. | Polymer film for wrapping a stent structure |
US5569198A (en) | 1995-01-23 | 1996-10-29 | Cortrak Medical Inc. | Microporous catheter |
US6017577A (en) | 1995-02-01 | 2000-01-25 | Schneider (Usa) Inc. | Slippery, tenaciously adhering hydrophilic polyurethane hydrogel coatings, coated polymer substrate materials, and coated medical devices |
US5919570A (en) | 1995-02-01 | 1999-07-06 | Schneider Inc. | Slippery, tenaciously adhering hydrogel coatings containing a polyurethane-urea polymer hydrogel commingled with a poly(N-vinylpyrrolidone) polymer hydrogel, coated polymer and metal substrate materials, and coated medical devices |
US5702754A (en) | 1995-02-22 | 1997-12-30 | Meadox Medicals, Inc. | Method of providing a substrate with a hydrophilic coating and substrates, particularly medical devices, provided with such coatings |
US5869127A (en) | 1995-02-22 | 1999-02-09 | Boston Scientific Corporation | Method of providing a substrate with a bio-active/biocompatible coating |
US6231600B1 (en) | 1995-02-22 | 2001-05-15 | Scimed Life Systems, Inc. | Stents with hybrid coating for medical devices |
US5854376A (en) | 1995-03-09 | 1998-12-29 | Sekisui Kaseihin Kogyo Kabushiki Kaisha | Aliphatic ester-amide copolymer resins |
US5605696A (en) | 1995-03-30 | 1997-02-25 | Advanced Cardiovascular Systems, Inc. | Drug loaded polymeric material and method of manufacture |
US6099562A (en) | 1996-06-13 | 2000-08-08 | Schneider (Usa) Inc. | Drug coating with topcoat |
US20020091433A1 (en) | 1995-04-19 | 2002-07-11 | Ni Ding | Drug release coated stent |
US5837313A (en) | 1995-04-19 | 1998-11-17 | Schneider (Usa) Inc | Drug release stent coating process |
US6120536A (en) | 1995-04-19 | 2000-09-19 | Schneider (Usa) Inc. | Medical devices with long term non-thrombogenic coatings |
KR19990007861A (en) | 1995-04-19 | 1999-01-25 | 가타오카가즈노리 | Heterotereric block copolymer and preparation method thereof |
US5674242A (en) | 1995-06-06 | 1997-10-07 | Quanam Medical Corporation | Endoprosthetic device with therapeutic compound |
US5609629A (en) | 1995-06-07 | 1997-03-11 | Med Institute, Inc. | Coated implantable medical device |
US5820917A (en) | 1995-06-07 | 1998-10-13 | Medtronic, Inc. | Blood-contacting medical device and method |
US7550005B2 (en) | 1995-06-07 | 2009-06-23 | Cook Incorporated | Coated implantable medical device |
US6774278B1 (en) | 1995-06-07 | 2004-08-10 | Cook Incorporated | Coated implantable medical device |
US6010530A (en) | 1995-06-07 | 2000-01-04 | Boston Scientific Technology, Inc. | Self-expanding endoluminal prosthesis |
US7611533B2 (en) | 1995-06-07 | 2009-11-03 | Cook Incorporated | Coated implantable medical device |
CA2178541C (en) | 1995-06-07 | 2009-11-24 | Neal E. Fearnot | Implantable medical device |
US5667767A (en) | 1995-07-27 | 1997-09-16 | Micro Therapeutics, Inc. | Compositions for use in embolizing blood vessels |
US5877224A (en) | 1995-07-28 | 1999-03-02 | Rutgers, The State University Of New Jersey | Polymeric drug formulations |
US5723219A (en) | 1995-12-19 | 1998-03-03 | Talison Research | Plasma deposited film networks |
US5658995A (en) | 1995-11-27 | 1997-08-19 | Rutgers, The State University | Copolymers of tyrosine-based polycarbonate and poly(alkylene oxide) |
DE19545678A1 (en) | 1995-12-07 | 1997-06-12 | Goldschmidt Ag Th | Copolymers of polyamino acid esters |
WO1997022371A1 (en) | 1995-12-18 | 1997-06-26 | Collagen Corporation | Crosslinked polymer compositions and methods for their use |
US6033582A (en) | 1996-01-22 | 2000-03-07 | Etex Corporation | Surface modification of medical implants |
US6054553A (en) | 1996-01-29 | 2000-04-25 | Bayer Ag | Process for the preparation of polymers having recurring agents |
US5932299A (en) | 1996-04-23 | 1999-08-03 | Katoot; Mohammad W. | Method for modifying the surface of an object |
US5955509A (en) | 1996-05-01 | 1999-09-21 | Board Of Regents, The University Of Texas System | pH dependent polymer micelles |
US5610241A (en) | 1996-05-07 | 1997-03-11 | Cornell Research Foundation, Inc. | Reactive graft polymer with biodegradable polymer backbone and method for preparing reactive biodegradable polymers |
US5876433A (en) | 1996-05-29 | 1999-03-02 | Ethicon, Inc. | Stent and method of varying amounts of heparin coated thereon to control treatment |
US5874165A (en) | 1996-06-03 | 1999-02-23 | Gore Enterprise Holdings, Inc. | Materials and method for the immobilization of bioactive species onto polymeric subtrates |
NL1003459C2 (en) | 1996-06-28 | 1998-01-07 | Univ Twente | Copoly (ester amides) and copoly (ester urethanes). |
US5711958A (en) | 1996-07-11 | 1998-01-27 | Life Medical Sciences, Inc. | Methods for reducing or eliminating post-surgical adhesion formation |
WO1998003218A1 (en) * | 1996-07-23 | 1998-01-29 | Scimed Life Systems, Inc. | High compliance, high strength catheter balloons useful for treatment of gastrointestinal lesions |
US5830178A (en) | 1996-10-11 | 1998-11-03 | Micro Therapeutics, Inc. | Methods for embolizing vascular sites with an emboilizing composition comprising dimethylsulfoxide |
US6060518A (en) | 1996-08-16 | 2000-05-09 | Supratek Pharma Inc. | Polymer compositions for chemotherapy and methods of treatment using the same |
US5783657A (en) | 1996-10-18 | 1998-07-21 | Union Camp Corporation | Ester-terminated polyamides of polymerized fatty acids useful in formulating transparent gels in low polarity liquids |
US6530951B1 (en) | 1996-10-24 | 2003-03-11 | Cook Incorporated | Silver implantable medical device |
US6120491A (en) | 1997-11-07 | 2000-09-19 | The State University Rutgers | Biodegradable, anionic polymers derived from the amino acid L-tyrosine |
DE19652037A1 (en) | 1996-12-13 | 1998-06-18 | Wolff Walsrode Ag | Elastic films with improved biodegradability and processes for their production |
US5980972A (en) | 1996-12-20 | 1999-11-09 | Schneider (Usa) Inc | Method of applying drug-release coatings |
US5997517A (en) | 1997-01-27 | 1999-12-07 | Sts Biopolymers, Inc. | Bonding layers for medical device surface coatings |
DE69828387T2 (en) | 1997-01-28 | 2005-12-08 | United States Surgical Corp., Norwalk | POLYESTERAMIDE, ITS PRESENTATION AND SURGICAL FABRICATED SURGICAL ARTICLES |
ES2192762T3 (en) | 1997-01-28 | 2003-10-16 | United States Surgical Corp | POLYESTERAMIDE, ITS PREPARATION AND SURGICAL DEVICES MANUFACTURED FROM IT. |
CA2279270C (en) | 1997-01-28 | 2007-05-15 | United States Surgical Corporation | Polyesteramides with amino acid-derived groups alternating with alpha-hydroxyacid-derived groups and surgical articles made therefrom |
US6240616B1 (en) | 1997-04-15 | 2001-06-05 | Advanced Cardiovascular Systems, Inc. | Method of manufacturing a medicated porous metal prosthesis |
US5879697A (en) | 1997-04-30 | 1999-03-09 | Schneider Usa Inc | Drug-releasing coatings for medical devices |
US6245760B1 (en) | 1997-05-28 | 2001-06-12 | Aventis Pharmaceuticals Products, Inc | Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases |
US6180632B1 (en) | 1997-05-28 | 2001-01-30 | Aventis Pharmaceuticals Products Inc. | Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases |
US6159978A (en) | 1997-05-28 | 2000-12-12 | Aventis Pharmaceuticals Product, Inc. | Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases |
US6056993A (en) | 1997-05-30 | 2000-05-02 | Schneider (Usa) Inc. | Porous protheses and methods for making the same wherein the protheses are formed by spraying water soluble and water insoluble fibers onto a rotating mandrel |
US6110483A (en) | 1997-06-23 | 2000-08-29 | Sts Biopolymers, Inc. | Adherent, flexible hydrogel and medicated coatings |
US6211249B1 (en) | 1997-07-11 | 2001-04-03 | Life Medical Sciences, Inc. | Polyester polyether block copolymers |
US5980928A (en) | 1997-07-29 | 1999-11-09 | Terry; Paul B. | Implant for preventing conjunctivitis in cattle |
EP1009791A1 (en) | 1997-08-08 | 2000-06-21 | The Procter & Gamble Company | Laundry detergent compositions with amino acid based polymers to provide appearance and integrity benefits to fabrics laundered therewith |
US6121027A (en) | 1997-08-15 | 2000-09-19 | Surmodics, Inc. | Polybifunctional reagent having a polymeric backbone and photoreactive moieties and bioactive groups |
US6120788A (en) | 1997-10-16 | 2000-09-19 | Bioamide, Inc. | Bioabsorbable triglycolic acid poly(ester-amide)s |
US6015541A (en) | 1997-11-03 | 2000-01-18 | Micro Therapeutics, Inc. | Radioactive embolizing compositions |
US6110188A (en) | 1998-03-09 | 2000-08-29 | Corvascular, Inc. | Anastomosis method |
US6258371B1 (en) | 1998-04-03 | 2001-07-10 | Medtronic Inc | Method for making biocompatible medical article |
US20030040790A1 (en) | 1998-04-15 | 2003-02-27 | Furst Joseph G. | Stent coating |
US20010029351A1 (en) | 1998-04-16 | 2001-10-11 | Robert Falotico | Drug combinations and delivery devices for the prevention and treatment of vascular disease |
US7658727B1 (en) | 1998-04-20 | 2010-02-09 | Medtronic, Inc | Implantable medical device with enhanced biocompatibility and biostability |
US20020188037A1 (en) | 1999-04-15 | 2002-12-12 | Chudzik Stephen J. | Method and system for providing bioactive agent release coating |
DE69926017T2 (en) | 1998-04-27 | 2005-12-22 | SurModics, Inc., Eden Prairie | Bioactive agents releasing coatings |
FR2777895A1 (en) * | 1998-04-28 | 1999-10-29 | Debio Rech Pharma Sa | Non crosslinked block polymer useful as support for active agents e.g. antigens and vaccines |
US6113629A (en) | 1998-05-01 | 2000-09-05 | Micrus Corporation | Hydrogel for the therapeutic treatment of aneurysms |
KR100314496B1 (en) | 1998-05-28 | 2001-11-22 | 윤동진 | Non-thrombogenic heparin derivatives, process for preparation and use thereof |
US6153252A (en) | 1998-06-30 | 2000-11-28 | Ethicon, Inc. | Process for coating stents |
US6432543B2 (en) * | 1998-07-29 | 2002-08-13 | Basf Corporation | Decorative components having an elastomeric outer surface and methods of making such components |
WO2000010622A1 (en) | 1998-08-20 | 2000-03-02 | Cook Incorporated | Coated implantable medical device |
US6248127B1 (en) | 1998-08-21 | 2001-06-19 | Medtronic Ave, Inc. | Thromboresistant coated medical device |
US6335029B1 (en) | 1998-08-28 | 2002-01-01 | Scimed Life Systems, Inc. | Polymeric coatings for controlled delivery of active agents |
US6011125A (en) | 1998-09-25 | 2000-01-04 | General Electric Company | Amide modified polyesters |
US6530950B1 (en) | 1999-01-12 | 2003-03-11 | Quanam Medical Corporation | Intraluminal stent having coaxial polymer member |
US6419692B1 (en) | 1999-02-03 | 2002-07-16 | Scimed Life Systems, Inc. | Surface protection method for stents and balloon catheters for drug delivery |
US6143354A (en) | 1999-02-08 | 2000-11-07 | Medtronic Inc. | One-step method for attachment of biomolecules to substrate surfaces |
US6258121B1 (en) | 1999-07-02 | 2001-07-10 | Scimed Life Systems, Inc. | Stent coating |
US6283947B1 (en) | 1999-07-13 | 2001-09-04 | Advanced Cardiovascular Systems, Inc. | Local drug delivery injection catheter |
US6494862B1 (en) | 1999-07-13 | 2002-12-17 | Advanced Cardiovascular Systems, Inc. | Substance delivery apparatus and a method of delivering a therapeutic substance to an anatomical passageway |
US6177523B1 (en) | 1999-07-14 | 2001-01-23 | Cardiotech International, Inc. | Functionalized polyurethanes |
US6287628B1 (en) | 1999-09-03 | 2001-09-11 | Advanced Cardiovascular Systems, Inc. | Porous prosthesis and a method of depositing substances into the pores |
US6790228B2 (en) | 1999-12-23 | 2004-09-14 | Advanced Cardiovascular Systems, Inc. | Coating for implantable devices and a method of forming the same |
US6379381B1 (en) | 1999-09-03 | 2002-04-30 | Advanced Cardiovascular Systems, Inc. | Porous prosthesis and a method of depositing substances into the pores |
US6503954B1 (en) | 2000-03-31 | 2003-01-07 | Advanced Cardiovascular Systems, Inc. | Biocompatible carrier containing actinomycin D and a method of forming the same |
US6503556B2 (en) | 2000-12-28 | 2003-01-07 | Advanced Cardiovascular Systems, Inc. | Methods of forming a coating for a prosthesis |
US6749626B1 (en) | 2000-03-31 | 2004-06-15 | Advanced Cardiovascular Systems, Inc. | Actinomycin D for the treatment of vascular disease |
US20040029952A1 (en) | 1999-09-03 | 2004-02-12 | Yung-Ming Chen | Ethylene vinyl alcohol composition and coating |
US6713119B2 (en) | 1999-09-03 | 2004-03-30 | Advanced Cardiovascular Systems, Inc. | Biocompatible coating for a prosthesis and a method of forming the same |
US6759054B2 (en) | 1999-09-03 | 2004-07-06 | Advanced Cardiovascular Systems, Inc. | Ethylene vinyl alcohol composition and coating |
US6203551B1 (en) | 1999-10-04 | 2001-03-20 | Advanced Cardiovascular Systems, Inc. | Chamber for applying therapeutic substances to an implant device |
US6331313B1 (en) | 1999-10-22 | 2001-12-18 | Oculex Pharmaceticals, Inc. | Controlled-release biocompatible ocular drug delivery implant devices and methods |
US6251136B1 (en) | 1999-12-08 | 2001-06-26 | Advanced Cardiovascular Systems, Inc. | Method of layering a three-coated stent using pharmacological and polymeric agents |
US6613432B2 (en) | 1999-12-22 | 2003-09-02 | Biosurface Engineering Technologies, Inc. | Plasma-deposited coatings, devices and methods |
US6908624B2 (en) | 1999-12-23 | 2005-06-21 | Advanced Cardiovascular Systems, Inc. | Coating for implantable devices and a method of forming the same |
US6283949B1 (en) | 1999-12-27 | 2001-09-04 | Advanced Cardiovascular Systems, Inc. | Refillable implantable drug delivery pump |
WO2001047572A2 (en) | 1999-12-29 | 2001-07-05 | Advanced Cardiovascular Systems, Inc. | Device and active component for inhibiting formation of thrombus-inflammatory cell matrix |
US6527801B1 (en) | 2000-04-13 | 2003-03-04 | Advanced Cardiovascular Systems, Inc. | Biodegradable drug delivery material for stent |
US20020007215A1 (en) | 2000-05-19 | 2002-01-17 | Robert Falotico | Drug/drug delivery systems for the prevention and treatment of vascular disease |
US20020007214A1 (en) | 2000-05-19 | 2002-01-17 | Robert Falotico | Drug/drug delivery systems for the prevention and treatment of vascular disease |
US20020007213A1 (en) | 2000-05-19 | 2002-01-17 | Robert Falotico | Drug/drug delivery systems for the prevention and treatment of vascular disease |
US20020005206A1 (en) | 2000-05-19 | 2002-01-17 | Robert Falotico | Antiproliferative drug and delivery device |
US6776796B2 (en) | 2000-05-12 | 2004-08-17 | Cordis Corportation | Antiinflammatory drug and delivery device |
US6395326B1 (en) | 2000-05-31 | 2002-05-28 | Advanced Cardiovascular Systems, Inc. | Apparatus and method for depositing a coating onto a surface of a prosthesis |
US6673385B1 (en) | 2000-05-31 | 2004-01-06 | Advanced Cardiovascular Systems, Inc. | Methods for polymeric coatings stents |
US6585765B1 (en) | 2000-06-29 | 2003-07-01 | Advanced Cardiovascular Systems, Inc. | Implantable device having substances impregnated therein and a method of impregnating the same |
US20020077693A1 (en) | 2000-12-19 | 2002-06-20 | Barclay Bruce J. | Covered, coiled drug delivery stent and method |
US6555157B1 (en) | 2000-07-25 | 2003-04-29 | Advanced Cardiovascular Systems, Inc. | Method for coating an implantable device and system for performing the method |
MXPA03000821A (en) | 2000-07-27 | 2004-03-18 | Univ Rutgers | Therapeutic polyesters and polyamides. |
US6451373B1 (en) | 2000-08-04 | 2002-09-17 | Advanced Cardiovascular Systems, Inc. | Method of forming a therapeutic coating onto a surface of an implantable prosthesis |
US6503538B1 (en) * | 2000-08-30 | 2003-01-07 | Cornell Research Foundation, Inc. | Elastomeric functional biodegradable copolyester amides and copolyester urethanes |
US6585926B1 (en) | 2000-08-31 | 2003-07-01 | Advanced Cardiovascular Systems, Inc. | Method of manufacturing a porous balloon |
US6254632B1 (en) | 2000-09-28 | 2001-07-03 | Advanced Cardiovascular Systems, Inc. | Implantable medical device having protruding surface structures for drug delivery and cover attachment |
US6716444B1 (en) | 2000-09-28 | 2004-04-06 | Advanced Cardiovascular Systems, Inc. | Barriers for polymer-coated implantable medical devices and methods for making the same |
US20020051730A1 (en) | 2000-09-29 | 2002-05-02 | Stanko Bodnar | Coated medical devices and sterilization thereof |
US20020111590A1 (en) | 2000-09-29 | 2002-08-15 | Davila Luis A. | Medical devices, drug coatings and methods for maintaining the drug coatings thereon |
US6746773B2 (en) | 2000-09-29 | 2004-06-08 | Ethicon, Inc. | Coatings for medical devices |
US7261735B2 (en) | 2001-05-07 | 2007-08-28 | Cordis Corporation | Local drug delivery devices and methods for maintaining the drug coatings thereon |
US6506437B1 (en) | 2000-10-17 | 2003-01-14 | Advanced Cardiovascular Systems, Inc. | Methods of coating an implantable device having depots formed in a surface thereof |
US6558733B1 (en) | 2000-10-26 | 2003-05-06 | Advanced Cardiovascular Systems, Inc. | Method for etching a micropatterned microdepot prosthesis |
US6758859B1 (en) | 2000-10-30 | 2004-07-06 | Kenny L. Dang | Increased drug-loading and reduced stress drug delivery device |
US7077859B2 (en) | 2000-12-22 | 2006-07-18 | Avantec Vascular Corporation | Apparatus and methods for variably controlled substance delivery from implanted prostheses |
US6824559B2 (en) * | 2000-12-22 | 2004-11-30 | Advanced Cardiovascular Systems, Inc. | Ethylene-carboxyl copolymers as drug delivery matrices |
US20020082679A1 (en) | 2000-12-22 | 2002-06-27 | Avantec Vascular Corporation | Delivery or therapeutic capable agents |
US6544543B1 (en) | 2000-12-27 | 2003-04-08 | Advanced Cardiovascular Systems, Inc. | Periodic constriction of vessels to treat ischemic tissue |
US6540776B2 (en) | 2000-12-28 | 2003-04-01 | Advanced Cardiovascular Systems, Inc. | Sheath for a prosthesis and methods of forming the same |
US6663662B2 (en) | 2000-12-28 | 2003-12-16 | Advanced Cardiovascular Systems, Inc. | Diffusion barrier layer for implantable devices |
US20020087123A1 (en) | 2001-01-02 | 2002-07-04 | Hossainy Syed F.A. | Adhesion of heparin-containing coatings to blood-contacting surfaces of medical devices |
US6645195B1 (en) | 2001-01-05 | 2003-11-11 | Advanced Cardiovascular Systems, Inc. | Intraventricularly guided agent delivery system and method of use |
US6544223B1 (en) | 2001-01-05 | 2003-04-08 | Advanced Cardiovascular Systems, Inc. | Balloon catheter for delivering therapeutic agents |
US6544582B1 (en) | 2001-01-05 | 2003-04-08 | Advanced Cardiovascular Systems, Inc. | Method and apparatus for coating an implantable device |
US6740040B1 (en) | 2001-01-30 | 2004-05-25 | Advanced Cardiovascular Systems, Inc. | Ultrasound energy driven intraventricular catheter to treat ischemia |
US20030032767A1 (en) | 2001-02-05 | 2003-02-13 | Yasuhiro Tada | High-strength polyester-amide fiber and process for producing the same |
WO2002064014A2 (en) | 2001-02-09 | 2002-08-22 | Endoluminal Therapeutics, Inc. | Endomural therapy |
US20030004141A1 (en) | 2001-03-08 | 2003-01-02 | Brown David L. | Medical devices, compositions and methods for treating vulnerable plaque |
US6780424B2 (en) | 2001-03-30 | 2004-08-24 | Charles David Claude | Controlled morphologies in polymer drug for release of drugs from polymer films |
US6623448B2 (en) | 2001-03-30 | 2003-09-23 | Advanced Cardiovascular Systems, Inc. | Steerable drug delivery device |
US6645135B1 (en) | 2001-03-30 | 2003-11-11 | Advanced Cardiovascular Systems, Inc. | Intravascular catheter device and method for simultaneous local delivery of radiation and a therapeutic substance |
US6625486B2 (en) | 2001-04-11 | 2003-09-23 | Advanced Cardiovascular Systems, Inc. | Method and apparatus for intracellular delivery of an agent |
US6764505B1 (en) | 2001-04-12 | 2004-07-20 | Advanced Cardiovascular Systems, Inc. | Variable surface area stent |
US6712845B2 (en) | 2001-04-24 | 2004-03-30 | Advanced Cardiovascular Systems, Inc. | Coating for a stent and a method of forming the same |
NZ528994A (en) | 2001-04-26 | 2006-02-24 | Control Delivery Sys Inc | Sustained release drug delivery system containing codrugs |
US6660034B1 (en) | 2001-04-30 | 2003-12-09 | Advanced Cardiovascular Systems, Inc. | Stent for increasing blood flow to ischemic tissues and a method of using the same |
US6656506B1 (en) | 2001-05-09 | 2003-12-02 | Advanced Cardiovascular Systems, Inc. | Microparticle coated medical device |
US7651695B2 (en) | 2001-05-18 | 2010-01-26 | Advanced Cardiovascular Systems, Inc. | Medicated stents for the treatment of vascular disease |
US6743462B1 (en) | 2001-05-31 | 2004-06-01 | Advanced Cardiovascular Systems, Inc. | Apparatus and method for coating implantable devices |
US7862495B2 (en) | 2001-05-31 | 2011-01-04 | Advanced Cardiovascular Systems, Inc. | Radiation or drug delivery source with activity gradient to minimize edge effects |
US6605154B1 (en) | 2001-05-31 | 2003-08-12 | Advanced Cardiovascular Systems, Inc. | Stent mounting device |
US6666880B1 (en) | 2001-06-19 | 2003-12-23 | Advised Cardiovascular Systems, Inc. | Method and system for securing a coated stent to a balloon catheter |
US6572644B1 (en) | 2001-06-27 | 2003-06-03 | Advanced Cardiovascular Systems, Inc. | Stent mounting device and a method of using the same to coat a stent |
US6695920B1 (en) | 2001-06-27 | 2004-02-24 | Advanced Cardiovascular Systems, Inc. | Mandrel for supporting a stent and a method of using the mandrel to coat a stent |
US6565659B1 (en) | 2001-06-28 | 2003-05-20 | Advanced Cardiovascular Systems, Inc. | Stent mounting assembly and a method of using the same to coat a stent |
US6673154B1 (en) | 2001-06-28 | 2004-01-06 | Advanced Cardiovascular Systems, Inc. | Stent mounting device to coat a stent |
US6706013B1 (en) | 2001-06-29 | 2004-03-16 | Advanced Cardiovascular Systems, Inc. | Variable length drug delivery catheter |
US6656216B1 (en) | 2001-06-29 | 2003-12-02 | Advanced Cardiovascular Systems, Inc. | Composite stent with regioselective material |
US6527863B1 (en) | 2001-06-29 | 2003-03-04 | Advanced Cardiovascular Systems, Inc. | Support device for a stent and a method of using the same to coat a stent |
EP1273314A1 (en) | 2001-07-06 | 2003-01-08 | Terumo Kabushiki Kaisha | Stent |
US6641611B2 (en) | 2001-11-26 | 2003-11-04 | Swaminathan Jayaraman | Therapeutic coating for an intravascular implant |
JP2005504813A (en) | 2001-09-24 | 2005-02-17 | メドトロニック・エイヴイイー・インコーポレーテッド | Rational drug therapy device and method |
US7195640B2 (en) | 2001-09-25 | 2007-03-27 | Cordis Corporation | Coated medical devices for the treatment of vulnerable plaque |
US6753071B1 (en) | 2001-09-27 | 2004-06-22 | Advanced Cardiovascular Systems, Inc. | Rate-reducing membrane for release of an agent |
US20030059520A1 (en) | 2001-09-27 | 2003-03-27 | Yung-Ming Chen | Apparatus for regulating temperature of a composition and a method of coating implantable devices |
US20030065377A1 (en) | 2001-09-28 | 2003-04-03 | Davila Luis A. | Coated medical devices |
US20030073961A1 (en) | 2001-09-28 | 2003-04-17 | Happ Dorrie M. | Medical device containing light-protected therapeutic agent and a method for fabricating thereof |
WO2003034944A1 (en) * | 2001-10-15 | 2003-05-01 | Hemoteq Gmbh | Coating of stents for preventing restenosis |
US7585516B2 (en) | 2001-11-12 | 2009-09-08 | Advanced Cardiovascular Systems, Inc. | Coatings for drug delivery devices |
US6663880B1 (en) | 2001-11-30 | 2003-12-16 | Advanced Cardiovascular Systems, Inc. | Permeabilizing reagents to increase drug delivery and a method of local delivery |
US6709514B1 (en) | 2001-12-28 | 2004-03-23 | Advanced Cardiovascular Systems, Inc. | Rotary coating apparatus for coating implantable medical devices |
EP1382628A1 (en) * | 2002-07-16 | 2004-01-21 | Polyganics B.V. | Biodegradable phase separated segmented/block co-polyesters |
US20040054104A1 (en) | 2002-09-05 | 2004-03-18 | Pacetti Stephen D. | Coatings for drug delivery devices comprising modified poly(ethylene-co-vinyl alcohol) |
US20040063805A1 (en) | 2002-09-19 | 2004-04-01 | Pacetti Stephen D. | Coatings for implantable medical devices and methods for fabrication thereof |
US7087263B2 (en) | 2002-10-09 | 2006-08-08 | Advanced Cardiovascular Systems, Inc. | Rare limiting barriers for implantable medical devices |
US7220816B2 (en) * | 2003-12-16 | 2007-05-22 | Advanced Cardiovascular Systems, Inc. | Biologically absorbable coatings for implantable devices based on poly(ester amides) and methods for fabricating the same |
-
2004
- 2004-03-16 US US10/805,036 patent/US8685431B2/en not_active Expired - Fee Related
-
2005
- 2005-03-08 EP EP20050735299 patent/EP1789105A2/en not_active Withdrawn
- 2005-03-08 WO PCT/US2005/007895 patent/WO2005089824A2/en active Application Filing
- 2005-03-08 JP JP2007503966A patent/JP2007529270A/en active Pending
-
2014
- 2014-01-30 US US14/168,806 patent/US20140147686A1/en not_active Abandoned
- 2014-01-30 US US14/168,903 patent/US20140147687A1/en not_active Abandoned
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5358677A (en) * | 1992-03-17 | 1994-10-25 | United States Surgical Corporation | Methods of forming bioabsorbable objects from polyvinyl alcohol |
DE19753532A1 (en) * | 1997-12-03 | 1999-06-10 | Bayer Ag | Easily produced random polyether-ester-amides with high water vapor permeability, suitable for film extrusion |
US6344535B1 (en) * | 1997-12-03 | 2002-02-05 | Bayer Aktiengesellschaft | Polyether ester amides |
EP1236757A1 (en) * | 1999-09-30 | 2002-09-04 | Sekisui Chemical Co., Ltd. | Thermoplastic elastomer, use thereof, and process for producing the same |
US20020015720A1 (en) * | 2000-01-11 | 2002-02-07 | Ramaz Katsarava | Polymer blends as biodegradable matrices for preparing biocomposites |
US20020065553A1 (en) * | 2000-11-28 | 2002-05-30 | Scimed Life System, Inc. | Method for manufacturing a medical device having a coated portion by laser ablation |
Also Published As
Publication number | Publication date |
---|---|
US8685431B2 (en) | 2014-04-01 |
WO2005089824A3 (en) | 2005-11-17 |
US20140147686A1 (en) | 2014-05-29 |
US20050208091A1 (en) | 2005-09-22 |
WO2005089824A2 (en) | 2005-09-29 |
EP1789105A2 (en) | 2007-05-30 |
JP2007529270A (en) | 2007-10-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8685431B2 (en) | Biologically absorbable coatings for implantable devices based on copolymers having ester bonds and methods for fabricating the same | |
US7538180B2 (en) | Biologically absorbable coatings for implantable devices based on poly(ester amides) and methods for fabricating the same | |
US7435788B2 (en) | Biobeneficial polyamide/polyethylene glycol polymers for use with drug eluting stents | |
US8003123B2 (en) | Biologically absorbable coatings for implantable devices and methods for fabricating the same | |
US7455907B2 (en) | Hydrophobic biologically absorbable coatings for drug delivery devices and methods for fabricating the same | |
US20050112170A1 (en) | Coatings for implantable devices comprising polymers of lactic acid and methods for fabricating the same | |
US20050106204A1 (en) | Biologically beneficial coatings for implantable devices containing fluorinated polymers and methods for fabricating the same | |
US20060095122A1 (en) | Implantable devices comprising biologically absorbable star polymers and methods for fabricating the same | |
EP1805246A1 (en) | End-capped poly(ester amide) copolymers | |
US20080175882A1 (en) | Polymers of aliphatic thioester | |
US9408949B2 (en) | Coatings for implantable devices comprising polymers of lactic acid and methods for fabricating the same | |
US9067000B2 (en) | End-capped poly(ester amide) copolymers |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |